1
|
Irshad HA, Shariq SF, Khan MAA, Shaikh T, Kakar WG, Shakir M, Hankinson TC, Enam SA. Delay in the Diagnosis of Pediatric Brain Tumors in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. Neurosurgery 2025; 96:289-297. [PMID: 38984834 DOI: 10.1227/neu.0000000000003097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2024] [Accepted: 05/23/2024] [Indexed: 07/11/2024] Open
Abstract
BACKGROUND AND OBJECTIVES Vague symptoms and a lack of pathognomonic features hinder the timely diagnosis of pediatric brain tumors (PBTs). However, patients in low- and middle-income countries (LMICs) must also bear the brunt of a multitude of additional factors contributing to diagnostic delays and subsequently affecting survival. Therefore, this study aims to assess these factors and quantify the durations associated with diagnostic delays for PBTs in LMICs. METHODS A systematic review of extant literature regarding children from LMICs diagnosed with brain tumors was conducted. Articles published before June 2023 were identified using PubMed, Google Scholar, Scopus, Embase, Cumulative Index to Nursing and Allied Health Literature, and Web of Science. A meta-analysis was conducted using a random-effects model through R Statistical Software. Quality was assessed using the Newcastle Ottawa Scale. RESULTS A total of 40 studies including 2483 patients with PBT from 21 LMICs were identified. Overall, nonspecific symptoms (62.5%) and socioeconomic status (45.0%) were the most frequently reported factors contributing to diagnostic delays. Potential sources of patient-associated delay included lack of parental awareness (45.0%) and financial constraints (42.5%). Factors contributing to health care system delays included misdiagnoses (42.5%) and improper referrals (32.5%). A pooled mean prediagnostic symptomatic interval was calculated to be 230.77 days (127.58-333.96), the patient-associated delay was 146.02 days (16.47-275.57), and the health care system delay was 225.05 days (-64.79 to 514.89). CONCLUSION A multitude of factors contribute to diagnostic delays in LMICs. The disproportionate effect of these factors is demonstrated by the long interval between symptom onset and the definitive diagnosis of PBTs in LMICs, when compared with high-income countries. While evidence-based policy recommendations may improve the pace of diagnosis, policy makers will need to be cognizant of the unique challenges patients and health care systems face in LMICs.
Collapse
Affiliation(s)
| | | | | | - Taha Shaikh
- Medical College, Aga Khan University, Karachi , Pakistan
| | | | - Muhammad Shakir
- Section of Neurosurgery, Department of Surgery, Aga Khan University Hospital, Karachi , Pakistan
| | - Todd C Hankinson
- Department of Neurosurgery, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora , Colorado , USA
| | - Syed Ather Enam
- Section of Neurosurgery, Department of Surgery, Aga Khan University Hospital, Karachi , Pakistan
| |
Collapse
|
2
|
Papyan R, Hovsepyan S, Hoveyan J, Hovhannisyan S, Arakelyan T, Tamamyan G, Sargsyan L, Hakobyan L, Davtyan L, Lazaryan A, Dallakyan D, Manukyan N, Mkhitaryan A, Grigoryan N, Perkowski S, Froehlich B, Groll A, Schiborr M, Glutig K, Kroeger K, Deventer N, Vaal MM, Wiebe K, Haier J, Hartmann W, Wardelmann E, Scheer M, Jürgens H. Breaking barriers: The impact of telemedicine on improving soft tissue and bone tumor management in Armenia. J Cancer Policy 2024; 43:100530. [PMID: 39672462 DOI: 10.1016/j.jcpo.2024.100530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2024] [Revised: 11/19/2024] [Accepted: 12/05/2024] [Indexed: 12/15/2024]
Abstract
PURPOSE Musculoskeletal sarcomas are a rare group of malignant neoplasms, accounting for approximately 12 % of all malignant neoplasms among children. Childhood cancer outcomes vary between developed and developing countries due to financial and educational inequalities. Telemedicine programs have a huge impact on the quality of cancer care, helping to optimize resources for better cancer care in a resource-limited setting. In 2019, Armenia established multidisciplinary teams (MDT) with the guidance of international experts via telemedicine, significantly improving patients' management diagnosed with sarcomas. METHODS The musculoskeletal cancer working group, mentored by the University Hospital of Münster (UKM), conducted weekly virtual tumor boards to discuss cases, focusing on the review of pathological and radiological examinations. RESULTS From August 2019 to December 2023, the musculoskeletal cancer MDT discussed 151 musculoskeletal tumor cases via 74 MDT meetings. Imaging studies of all discussed cases were reviewed, while the review of histology images was performed for 93 % of cases. The pathology review led to changes in previously established diagnoses in eleven cases, which subsequently changed management. These led to altered local control strategies for 32 patients, with 5 requiring treatment abroad, and changes in chemotherapy regimens for 17 patients. Notably, there were no cases of treatment refusal post-implementation, a reduction from the previous 3 % refusal rate. CONCLUSION The successful telemedicine initiative, coupled with institutional support, improved the care of patients diagnosed with musculoskeletal tumors. The investment in telemedicine in developing countries not only enhances communications with international and local experts across various disciplines but also significantly improves the handling of patients diagnosed with sarcomas.
Collapse
Affiliation(s)
- Ruzanna Papyan
- Department of Hematology and Pediatric Oncology, Yerevan State Medical University, Yerevan, Armenia; Pediatric Cancer and Blood Disorders Center of Armenia, Yeolyan Hematology and Oncology Center, Yerevan, Armenia; Immune Oncology Research Institute, Yerevan, Armenia.
| | - Shushan Hovsepyan
- Department of Hematology and Pediatric Oncology, Yerevan State Medical University, Yerevan, Armenia; Pediatric Cancer and Blood Disorders Center of Armenia, Yeolyan Hematology and Oncology Center, Yerevan, Armenia; Immune Oncology Research Institute, Yerevan, Armenia
| | - Julieta Hoveyan
- Pediatric Cancer and Blood Disorders Center of Armenia, Yeolyan Hematology and Oncology Center, Yerevan, Armenia; Immune Oncology Research Institute, Yerevan, Armenia
| | - Saten Hovhannisyan
- Department of Hematology and Pediatric Oncology, Yerevan State Medical University, Yerevan, Armenia; Pediatric Cancer and Blood Disorders Center of Armenia, Yeolyan Hematology and Oncology Center, Yerevan, Armenia
| | | | - Gevorg Tamamyan
- Department of Hematology and Pediatric Oncology, Yerevan State Medical University, Yerevan, Armenia; Pediatric Cancer and Blood Disorders Center of Armenia, Yeolyan Hematology and Oncology Center, Yerevan, Armenia; Immune Oncology Research Institute, Yerevan, Armenia
| | - Lilit Sargsyan
- Department of Hematology and Pediatric Oncology, Yerevan State Medical University, Yerevan, Armenia; Pediatric Cancer and Blood Disorders Center of Armenia, Yeolyan Hematology and Oncology Center, Yerevan, Armenia
| | - Lusine Hakobyan
- Department of Hematology and Pediatric Oncology, Yerevan State Medical University, Yerevan, Armenia; Pediatric Cancer and Blood Disorders Center of Armenia, Yeolyan Hematology and Oncology Center, Yerevan, Armenia
| | | | - Armine Lazaryan
- National Center of Oncology named after V.A. Fanarjyan, Yerevan, Armenia; Ira Medical Group, Yerevan, Armenia
| | | | - Narek Manukyan
- National Center of Oncology named after V.A. Fanarjyan, Yerevan, Armenia
| | - Armen Mkhitaryan
- Histogen Armenian-German Scientific Center of Pathology, Yerevan, Armenia
| | - Nelli Grigoryan
- National Center of Oncology named after V.A. Fanarjyan, Yerevan, Armenia
| | - Sybille Perkowski
- Clinic for Pediatric and Neonatal Surgery, University Hospital Münster, Münster, Germany
| | - Birgit Froehlich
- Department of Pediatric Hematology and Oncology, University Hospital Münster, Münster, Germany
| | - Andreas Groll
- Department of Pediatric Hematology and Oncology, University Hospital Münster, Münster, Germany
| | - Manfred Schiborr
- Department of Pediatric Radiology, University Hospital Münster, Münster, Germany
| | - Katja Glutig
- Department of Pediatric Radiology, University Hospital Münster, Münster, Germany
| | - Kai Kroeger
- Department of Radiation Oncology, University Hospital Münster, Münster, Germany
| | - Niklas Deventer
- Department of Orthopedic Oncology, University Hospital Münster, Münster, Germany
| | | | - Karsten Wiebe
- Department of Chest Surgery, University Hospital Münster, Münster, Germany
| | - Joerg Haier
- Department of Chest Surgery, University Hospital Münster, Münster, Germany
| | - Wolfgang Hartmann
- Comprehensive Cancer Center, Hannover Medical School, Hanover, Germany
| | - Eva Wardelmann
- Department of Pathology, University Hospital Münster, Münster, Germany
| | - Monika Scheer
- Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
| | - Heribert Jürgens
- Department of Pediatric Hematology and Oncology, University Hospital Münster, Münster, Germany
| |
Collapse
|
3
|
Kili A, ElKababri M, Coze C, Patte C, Van Heerden J, Martelli H, Harif M, Hessissen L. A Transformative Decade: An Evaluation of the Francophone African Group of Pediatric Oncology's Training Program (2014-2024). JOURNAL OF CANCER EDUCATION : THE OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER EDUCATION 2024:10.1007/s13187-024-02499-6. [PMID: 39235549 DOI: 10.1007/s13187-024-02499-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 08/27/2024] [Indexed: 09/06/2024]
Abstract
Childhood cancer in Africa faces significant challenges due to workforce shortages and limited training opportunities. The French African Group for Pediatric Oncology (GFAOP) established the African School of Pediatric Oncology and introduced a pediatric oncology teaching called the "Diplome Universitaire de Cancérologie Pédiatrique" (DUCP) training program. This report evaluates the contributions of the DUCP program to pediatric oncology in Africa and discusses the sustainability of the program. The DUCP program trained six cohorts of healthcare professionals from French-speaking African countries since 2014. An evaluation was done on the participant demographics and regional contributions. Data were collected from trainee records and DUCP records. The DUCP program was evaluated based on the domains developed by the Education Program Assessment Tool (EPAT). Over the 10-year period, the DUCP program trained 107 healthcare professionals from 20 Francophone countries of which 99% were retained in Africa. Of the 83 graduates, 55 (66%) actively practice in pediatric oncology. Of the 18 francophone countries, 17 countries increased the number of pediatric oncologists and 16 improved the ratio of pediatric oncologists to children under 15 years. Nine new pediatric oncology services were established by the graduates thus far. Despite challenges, such as the COVID-19 pandemic, the program remains sustainable because of continued financial support, collaborations with the international pediatric oncology community, and adapting the program content to participant and local setting needs. Retention of graduates in childhood cancer services remains a challenge that necessitates governmental involvement. The DUCP program is impactful and sustainable and improves access for children to cancer services in Africa. By fostering continued collaboration with governments, addressing the needs of an increasing African population, and expanding support for similar initiatives, the program's longevity and positive impact can be further ensured.
Collapse
Affiliation(s)
- Amina Kili
- Pediatric Hematology and Oncology Department, University Mohammed V, Rabat, Morocco
| | - Maria ElKababri
- Pediatric Hematology and Oncology Department, University Mohammed V, Rabat, Morocco
| | - Carole Coze
- Aix Marseille University - Assistance Publique Des Hôpitaux de Marseille, Marseille, France
| | - Catherine Patte
- Francophone African Group of Pediatric Oncology, Villejuif, France
| | - Jaques Van Heerden
- Department of Paediatric Oncology, Antwerp University Hospital, Antwerp, Belgium
| | - Hélène Martelli
- Francophone African Group of Pediatric Oncology, Villejuif, France
| | - Mhamed Harif
- Francophone African Group of Pediatric Oncology, Villejuif, France
| | - Laila Hessissen
- Pediatric Hematology and Oncology Department, University Mohammed V, Rabat, Morocco.
- Francophone African Group of Pediatric Oncology, Villejuif, France.
| |
Collapse
|
4
|
Carson L, Petricca K, Denburg A. The promise of POSIT: Real-world application of the Paediatric Oncology System Integration Tool. J Cancer Policy 2024; 39:100454. [PMID: 37989453 DOI: 10.1016/j.jcpo.2023.100454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 10/14/2023] [Accepted: 11/13/2023] [Indexed: 11/23/2023]
Abstract
Childhood cancer presents significant acute and long-term challenges for patients,families, communities, and health systems. Although meaningful strides have been made in research and treatment, severe outcome disparities prevail between low- and middle-income countries (LMICs) and high-income countries (HICs), with childhood cancer survival rates lower than 20% in LMICs, as compared with over 80% across many HICs. In recent years, greater emphasis has been placed on health system strengthening as a means to develop domestic policy and capacity for sustainable improvements in childhood cancer outcomes in LMICs. In pursuit of a systems approach to childhood cancer in LMICs, our research team developed the Paediatric Oncology System Integration Tool (POSIT)-the first comprehensive framework for the design and evaluation of childhood cancer systems. Since its development, POSIT has been applied in an exploration of key determinants of access to essential childhood cancer medicines across two separate multi-site studies. In this commentary, we explore the value of the POSIT framework and toolkit as a constructive systems-level guide for examining interactions between childhood cancer-specific programs and encompassing health system. socio-political, and economic contexts.
Collapse
Affiliation(s)
- Laura Carson
- Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada
| | - Kadia Petricca
- Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada
| | - Avram Denburg
- Department of Paediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
| |
Collapse
|
5
|
Schantz C, Coulibaly A, Traoré A, Traoré BA, Faye K, Robin J, Teixeira L, Ridde V. Access to oncology care in Mali: a qualitative study on breast cancer. BMC Cancer 2024; 24:81. [PMID: 38225594 PMCID: PMC10788985 DOI: 10.1186/s12885-024-11825-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Accepted: 01/02/2024] [Indexed: 01/17/2024] Open
Abstract
BACKGROUND Breast cancer is the most common cancer in terms of incidence and mortality among women worldwide, including in Africa, and a rapid increase in the number of new cases of breast cancer has recently been observed in sub-Saharan Africa. Oncology is a relatively new discipline in many West African countries, particularly Mali; thus, little is known about the current state of cancer care infrastructure and oncology practices in these countries. METHODS To describe the challenges related to access to oncology care in Mali, we used a qualitative approach, following the Consolidated Criteria for Reporting Qualitative Research (COREQ). Thirty-eight semistructured interviews were conducted with health professionals treating cancer in Mali (n = 10), women with breast cancer (n = 25), and representatives of associations (n = 3), and 40 participant observations were conducted in an oncology unit in Bamako. We used the theoretical framework on access to health care developed by Levesque et al. a posteriori to organise and analyse the data collected. RESULTS Access to oncology care is partly limited by the current state of Mali's health infrastructure (technical platform failures, repeated strikes in university hospitals, incomplete free health care and the unavailability of medicines) and exacerbated by the security crisis that has been occurring the country since 2012. The lack of specialist doctors, combined with limited screening campaigns and a centralised and fragmented technical platform in Bamako, is particularly detrimental to breast cancer treatment. Women's lack of awareness, lack of information throughout the treatment process, stereotypes and opposition to amputations all play a significant role in their ability to seek and access quality care, leading some women to therapeutically wander and others to want to leave Mali. It also leaves them in debt and jeopardises the future of their children. However, the high level of trust in doctors, the involvement of international actors, the level of social support and the growing influence of civil society on the issue of cancer also represent great current opportunities to fight cancer in Mali. CONCLUSION Despite the efforts of successive Malian governments and the commitment of international actors, the provision of health care is still limited in the country, entrenching global inequalities in women's bodies.
Collapse
Affiliation(s)
- Clémence Schantz
- Université Paris Cité, IRD, Inserm, Ceped, F-75 006, Paris, France.
- Institution Convergences Et Migrations, Aubervilliers, France.
| | | | | | - Bakary Abou Traoré
- Centre de Santé de Référence de La Commune 2, Bamako, Mali
- Centre National de La Recherche Scientifique Et Technologie (CNRST), Bamako, Mali
| | - Kadiatou Faye
- Association Les Combattantes du Cancer, Bamako, Mali
| | - Julie Robin
- Université Paris Cité, IRD, Inserm, Ceped, F-75 006, Paris, France
| | - Luis Teixeira
- Pathophysiology of Breast Cancer Team, Department of Senology, Université Paris Cité INSERM U976, HIPIAP-HP, Hôpital Saint-Louis, Paris, France
| | - Valéry Ridde
- Université Paris Cité, IRD, Inserm, Ceped, F-75 006, Paris, France
| |
Collapse
|
6
|
Mensah ABB, Nunoo H, Boamah Mensah K, Okyere J, Dzomeku VM, Apiribu F, Agyenim Boateng K, Asoogo C, Opare-Lokko E, Clegg-Lamptey JN. Being the nurse for my child at home: A qualitative analysis of parental recognition, appraisal, and reactions to childhood cancer in Ghana. J Child Health Care 2023:13674935231225715. [PMID: 38154028 DOI: 10.1177/13674935231225715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2023]
Abstract
Parental involvement in childhood cancer care is of utmost importance, but the understanding of parental recognition, appraisal, and reactions to childhood cancer in settings such as Ghana is limited. We conducted an empirical phenomenological study to explore these aspects among Ghanaian parents. Twenty parents were purposively sampled to participate in semi-structured interviews between June and September 2022. All interviews were transcribed and analysed using an inductive thematic approach. We found that parents recognised symptoms through personal observation and their child's self-report, often perceiving them as non-severe. Emotional reactions upon receiving their child's cancer diagnosis included psychological distress, fear, doubts, and confusion. Enduring emotions experienced by parents were fears of disease recurrence and impending death of their child. Parents assumed the role of nurses at home, monitoring therapy effects, managing pain and symptoms, and dressing wounds. In conclusion, parents in Ghana play a crucial role in the recognition, diagnosis, and treatment pathways of childhood cancer. To enhance their ability to recognise symptoms and take timely actions, it is recommended to implement media programs and health education initiatives targeting parents.
Collapse
Affiliation(s)
- Adwoa Bemah Boamah Mensah
- School of Nursing and Midwifery, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
| | - Humaima Nunoo
- School of Nursing and Midwifery, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
- Onwe Government Hospital, Ejisu-Juaben, Ashanti region, Ghana
| | - Kofi Boamah Mensah
- Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
| | - Joshua Okyere
- School of Nursing and Midwifery, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
- Department of Population and Health, University of Cape Coast, Cape Coast, Ghana
| | - Veronica Millicent Dzomeku
- School of Nursing and Midwifery, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
| | - Felix Apiribu
- School of Nursing and Midwifery, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
| | - Kofi Agyenim Boateng
- College of Humanities and Social Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
| | - Comfort Asoogo
- Peadiatric Oncology Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana
| | - Edwina Opare-Lokko
- Faculty of Family Medicine, Ghana College of Surgeons and Physicians, Accra, Ghana
| | - Joe-Nat Clegg-Lamptey
- Department of Surgery, School of Medical Sciences, University of Ghana, Legon, Ghana
| |
Collapse
|
7
|
Mensah ABB, Nunoo H, Mensah KB, Okyere J, Dzomeku VM, Apiribu F, Asoogo C, Clegg-Lamptey JN. Impact of childhood and adolescence cancer on family caregivers: a qualitative analysis of strains, resources and coping behaviours. BMC Psychol 2023; 11:361. [PMID: 37898804 PMCID: PMC10612317 DOI: 10.1186/s40359-023-01406-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Accepted: 10/22/2023] [Indexed: 10/30/2023] Open
Abstract
BACKGROUND The physical demands of caring for children and adolescents diagnosed with cancer, over a lengthy period, exert significant strain on the health and well-being of family caregivers. The capacity of family caregivers to surmount and cope with the various strains they experience due to the diagnosis and treatment trajectory is essential to the quality of life of the child and adolescent who has been diagnosed with cancer. However, the experiences of family caregivers have been under-explored. This study explored the strains, resources, and coping strategies of family caregivers of children and adolescents diagnosed with cancer in Ghana. METHODS Guided by a descriptive phenomenological design, 20 semi-structured interviews with family caregivers were conducted at a tertiary health facility that provides paediatric oncology services. The study was conducted between June and October 2022. The interviews were transcribed verbatim, translated and coded using NVivo software. An inductive thematic analysis approach using Vaismoradi et al.'s thematic analysis framework was followed in analysing the data. RESULTS The study revealed that family caregivers of children diagnosed with cancer experienced three main strains: somatic strains (poor sleep quality, loss of appetite, and unintended weight loss), economic strains (financial burden and loss of economic livelihood), and psychosocial strains (isolation from social activities and network, frustration and helplessness, and balancing multiple family needs). The following themes emerged as coping resources: family cohesiveness, community support, and support from health care providers. Coping strategies that emerged included trusting in God and being self-motivated. CONCLUSION The study concludes that family caregivers experience somatic, economic, and psychosocial strains. However, they can leverage available resources (family cohesiveness, community support, and support from healthcare providers) to cope with these strains. There is a need to educate and sensitize family caregivers about the potential strains that they are likely to experience prior to the assumption of care roles. Also, the formal inclusion of non-governmental organizations and religious bodies will ensure that family caregivers receive sufficient community support to cope with the strains of caregiving.
Collapse
Affiliation(s)
- Adwoa Bemah Boamah Mensah
- School of Nursing and Midwifery, College of Health Sciences, Private Mail bag, Kwame Nkrumah University of Science and Technology, University Post Office, Kumasi, Ghana.
| | - Humaima Nunoo
- School of Nursing and Midwifery, College of Health Sciences, Private Mail bag, Kwame Nkrumah University of Science and Technology, University Post Office, Kumasi, Ghana
- Onwe Government Hospital, Ejusu District, Ejisu, Ghana
| | - Kofi Boamah Mensah
- Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, University Post Office, Private Mail bag, Kumasi, Ghana
| | - Joshua Okyere
- School of Nursing and Midwifery, College of Health Sciences, Private Mail bag, Kwame Nkrumah University of Science and Technology, University Post Office, Kumasi, Ghana
- Department of Population and Health, University of Cape Coast, University Post Office, Cape Coast, Ghana
| | - Veronica Millicent Dzomeku
- School of Nursing and Midwifery, College of Health Sciences, Private Mail bag, Kwame Nkrumah University of Science and Technology, University Post Office, Kumasi, Ghana
| | - Felix Apiribu
- School of Nursing and Midwifery, College of Health Sciences, Private Mail bag, Kwame Nkrumah University of Science and Technology, University Post Office, Kumasi, Ghana
| | - Comfort Asoogo
- Paediatric Oncology Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana
| | - Joe-Nat Clegg-Lamptey
- Department of Surgery, School of Medical Sciences, University of Ghana, Accra, Ghana
| |
Collapse
|
8
|
Majamanda MD, Chisoni F, Selemani A, Kearns I, Maree J. Paediatric oncology nursing education and training programmes: a scoping review protocol. BMJ Open 2023; 13:e070694. [PMID: 37813530 PMCID: PMC10565288 DOI: 10.1136/bmjopen-2022-070694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Accepted: 09/19/2023] [Indexed: 10/13/2023] Open
Abstract
INTRODUCTION The care of children with cancer is a highly specialised field which requires well-educated, trained and dedicated nurses to provide high-quality care. In low/middle-income countries, the survival rate of children with cancer is low as compared with that of high-income countries due to the limited number of specialised oncology healthcare professionals, especially nurses. To address this problem, a number of paediatric oncology education and training programmes have been developed for nurses. The objective of this scoping review is to describe the existing literature focusing on paediatric oncology nursing education and training programmes; to map the content, delivery methods, duration and mode of assessment. METHODS The review will include articles published in English, from 2012 to 2022, that describe a paediatric oncology nursing education programme, from any setting. The review will follow Joanna Briggs Institute methodology for scoping reviews guidelines. A systematic search of literature will be performed in CINAHL, Dimensions, Embase, PubMed and Scopus. A two-stage standardised screening process will be employed to evaluate eligibility of the articles. All abstracts that will be considered relevant will be reviewed in full text form by the two reviewers independently. Conflicts will be resolved by consensus of all reviewers through a meeting. Data will be extracted by two independent reviewers using a developed data extraction tool. The results will be reported in extraction tables and diagrams with a narrative summary. ETHICS AND DISSEMINATION This scoping review is part of the multiphase study which obtained ethical clearance from College of Medicine Research Ethics Committee in Malawi and Human Research Ethics Committee of the University of Witwatersrand, South Africa. The scoping review will be published in a peer reviewed journal. The findings will also be presented at national and international conferences. TRIAL REGISTRATION NUMBER https://doi.org/10.17605/OSF.IO/X3Q4H.
Collapse
Affiliation(s)
- Maureen Daisy Majamanda
- Child Health Nursing, Kamuzu University of Health Sciences, Blantyre, Malawi
- Consortium for Advanced Research Training in Africa, Nairobi, Kenya
- Nursing Education, University of the Witwatersrand, Johannesburg, South Africa
| | - Felix Chisoni
- Library, Kamuzu University of Health Sciences, Blantyre, Malawi
| | - Apatsa Selemani
- Consortium for Advanced Research Training in Africa, Nairobi, Kenya
- Library, Kamuzu University of Health Sciences, Blantyre, Malawi
- School of Public Health, University of the Witwatersrand, Johannesburg, South Africa
| | - Irene Kearns
- Nursing Education, University of the Witwatersrand, Johannesburg, South Africa
| | - Johanna Maree
- Nursing Education, University of the Witwatersrand, Johannesburg, South Africa
| |
Collapse
|
9
|
Elkina SM, Halvadzhiyan IB, Popova GT, Avdjieva-Tzavella DM, Stefanova E, Kaleva NN, Stoeva IH, Petrova CK, Iotova VM. First results of the growth disorders related twinning programme Partners4Growth implemented at the tertiary university pediatric endocrinology clinics in Bulgaria. J Pediatr Endocrinol Metab 2023; 36:832-841. [PMID: 37522427 DOI: 10.1515/jpem-2022-0584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Accepted: 07/11/2023] [Indexed: 08/01/2023]
Abstract
OBJECTIVES Early diagnosis of childhood growth disorders, their timely and proper treatment are important for better outcomes.The aim of the present study was to assess the results of the first 18 months of the growth disorders related twinning programme "Partners4Growth" implemented at all tertiary university pediatric endocrinology clinics in Bulgaria. METHODS In 2019, Partners4Growth started operation at 7 centres (4 experienced and 3 twin centres) with the main aim of aligning their practices in the shortest possible time. Education of twin centres' personnel was organized, equipment and methods for growth evaluation and follow-up were standardized. The approach was tested initially at one centre. At baseline and at the 18th month a questionnaire concerning diagnosis and management of recombinant human growth hormone (rhGH) requiring disorders was applied. RESULTS A total of 104 new patients were diagnosed compared to 30 in the previous year. Of those, 91 started rhGH treatment - 65 (64 %) GH deficient, 12 (12 %) Turner syndrome, 7 (7 %) Prader-Willi syndrome patients, and 7 (7 %) born small for gestational age without postnatal catch-up, representing 35.8 % of all currently rhGH treated Bulgarian children. A better geographical coverage and more advanced diagnostic and management practices were achieved. CONCLUSIONS Partners4Growth facilitated the alignment of the tertiary pediatric endocrinology centres competences thus leading to an improved diagnosis and treatment of growth disorders as well as better patients' access. For its short existence, the Programme increased significantly the number of new patients in the difficult times of COVID-19 pandemic thus justifying its continuation.
Collapse
Affiliation(s)
| | | | - Galina Ts Popova
- Clinic of Pediatrics, Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria
| | | | | | - Nartzis N Kaleva
- Department of Pediatrics and Medical Genetics, Medical University - Plovdiv, Plovdiv, Bulgaria
| | - Iva H Stoeva
- Department of Pediatrics, Medical University - Sofia, Sofia, Bulgaria
| | - Chayka K Petrova
- Department of Pediatrics, Medical University - Pleven, Pleven, Bulgaria
| | - Violeta M Iotova
- Department of Pediatrics, Medical University - Varna, Varna, Bulgaria
| |
Collapse
|
10
|
Erashdi M, Al-Ani A, Mansour A, Al-Hussaini M. Libyan cancer patients at King Hussein Cancer Center for more than a decade, the current situation, and a future vision. Front Oncol 2023; 12:1025757. [PMID: 36776359 PMCID: PMC9911041 DOI: 10.3389/fonc.2022.1025757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Accepted: 12/15/2022] [Indexed: 01/28/2023] Open
Abstract
Background Since 2011, the Libyan civil war crisis had affected all dimensions of livelihood including cancer care. This has resulted in a steady incline in the number of Libyan patients with cancer seeking oncologic care and management in Tunisia, Egypt and Jordan, among others. King Hussein Cancer Center (KHCC) has been one of the main destinations for Libyan patients with cancer for more than a decade. Aim We are reporting on the characteristics of Libyan patients with cancer presenting to KHCC during the past fourteen years. Methods We performed a retrospective chart review of all Libyan patients with cancer presenting to KHCC between 2006 and 2019. Results A total of 3170 records were included in the final analysis. The overall sample was predominantly adults (71%) with a male-to-female ratio of 1:1.2. Overall, the most common referred cancers to KHCC were breast (21%), hematolymphoid (HL) (17%), and gastrointestinal tract (GIT) (16.2%) cancers. Breast cancer was the most common among adult females (41.7%), GIT among adult males (23.6%), and HL among pediatrics (38.5%). Around 37.8% of patients presented with distant metastasis at their first encounter at KHCC, among which 14.7% were candidates for palliative care. Conclusion The sustenance of treatment for Libyan patients with cancer requires extensive collaboration between governmental and private sectors. The Libyan oncological landscape could benefit from national screening and awareness programs, twining programs and telemedicine, introduction of multidisciplinary boards, and the formulation of a national cancer registry. Adopting the successful models at KHCC can help to augment the oncology services within the Libyan healthcare sector.
Collapse
Affiliation(s)
- Madiha Erashdi
- Department of Pathology, James Cook University Hospital, South Tees National Health Service (NHS) Foundation Trust, Middlesbrough, United Kingdom
| | - Abdallah Al-Ani
- Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman, Jordan
| | - Asem Mansour
- Human Research Participants Protection Office, King Hussein Cancer Center, Amman, Jordan
| | - Maysa Al-Hussaini
- Human Research Participants Protection Office, King Hussein Cancer Center, Amman, Jordan,*Correspondence: Maysa Al-Hussaini,
| |
Collapse
|
11
|
Deribe L, Addissie A, Girma E, Abraha A, Adam H, Berbyuk Lindström N. Stress and coping strategies among parents of children with cancer at Tikur Anbessa Specialized Hospital paediatric oncology unit, Ethiopia: a phenomenological study. BMJ Open 2023; 13:e065090. [PMID: 36609328 PMCID: PMC9827240 DOI: 10.1136/bmjopen-2022-065090] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2022] [Accepted: 12/09/2022] [Indexed: 01/09/2023] Open
Abstract
OBJECTIVE This study explores sources of stress, conditions that help reduce stress levels and coping strategies among parents of children with cancer receiving chemotherapy at Tikur Anbessa Specialized Hospital (TASH) in Ethiopia. DESIGN A qualitative phenomenological approach was used. SETTING Parents of children receiving chemotherapy at the TASH paediatric oncology unit. PARTICIPANTS Fifteen semistructured in-depth interviews were conducted with nine mothers and six fathers of children with cancer from November 2020 to January 2021. RESULTS Sources of stress related to child's health condition as the severity of the child's illness, fear of treatment side effects and loss of body parts were identified. Parents mentioned experiencing stress arising from limited access to health facilities, long waiting times, prolonged hospital stays, lack of chemotherapy drugs, and limited or inadequate information about their child's disease condition and treatment. Other sources of stress were insufficient social support, stigmatisation of cancer and financial problems. Conditions decreasing parents' stress included positive changes in the child's health, receiving cancer treatment and access to drugs. Receiving counselling from healthcare providers, getting social support and knowing someone who had a positive treatment outcome also helped reduce stress. Coping strategies used by parents were religious practices including prayer, crying, accepting the child's condition, denial and communication with health providers. CONCLUSION The main causes of stress identified by parents of children with cancer in Ethiopia were the severity of their child's illness, expectations of poor treatment outcomes, unavailability of cancer treatment services and lack of social/financial support. Measures that should be considered to reduce parents' stress include providing psycho-oncological care for parents and improving the counselling available to parents concerning the nature of the child's illness, its treatment, diagnostic procedures and treatment side effects. It may also be helpful to establish and strengthen family support groups and parent-to-parent communication, improve the availability of chemotherapy drugs and offer more education on coping strategies.
Collapse
Affiliation(s)
- Leul Deribe
- Department of Nursing, School of Nursing and Midwifery, Addis Ababa University, Addis Ababa, Ethiopia
| | - Adamu Addissie
- Department of Preventive Medicine, School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia
| | - Eshetu Girma
- Department of Preventive Medicine, School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia
| | - Aynalem Abraha
- Department of Oncology, Addis Ababa University School of Medicine, Addis Ababa, Ethiopia
| | - Haileyesus Adam
- Department of Pediatrics and Child Health, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia
| | | |
Collapse
|
12
|
Bailey S, Davidson A, Parkes J, Tabori U, Figaji A, Epari S, Chinnaswamy G, Dias-Coronado R, Casavilca-Zambrano S, Amayiri N, Vassal G, Bouffet E, Clifford SC. How Can Genomic Innovations in Pediatric Brain Tumors Transform Outcomes in Low- and Middle-Income Countries? JCO Glob Oncol 2022; 8:e2200156. [PMID: 36252166 PMCID: PMC9812475 DOI: 10.1200/go.22.00156] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Pragmatic ways to apply molecular innovation to childhood brain cancer diagnosis and therapy in LMICs![]()
Collapse
Affiliation(s)
- Simon Bailey
- Great North Children's Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom,Simon Bailey, MBChB, PhD, Sir James Spence Institute of Child Health, Royal Victoria Infirmary, Queen Victoria Rd, Newcastle upon Tyne NE1 4LP, United Kingdom;
| | - Alan Davidson
- Haematology Oncology Service, Red Cross War Memorial Children's Hospital, Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa
| | - Jeannette Parkes
- Department of Radiation Oncology, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa
| | - Uri Tabori
- Neuro-oncology Program, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Anthony Figaji
- Department of Neurosurgery, Red Cross War Memorial Children's Hospital and University of Cape Town, Cape Town, South Africa
| | - Shridar Epari
- Department of Pathology, ACTREC and Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
| | - Girish Chinnaswamy
- Department of Pediatric Oncology, Tata Memorial Hospital, Parel, Mumbai, India
| | - Rosaldi Dias-Coronado
- Pediatric Oncology Department—Instituto Nacional de Enfermedades Neoplásicas, Surquillo, Peru
| | - Sandro Casavilca-Zambrano
- Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú and Facultad de Ciencias de la Salud de La Universidad de Huánuco, Huánuco, Peru
| | - Nisreen Amayiri
- Department of Hematology and Oncology, King Hussein Cancer Centre, Amman, Jordan
| | - Gilles Vassal
- Department of Pediatric and Adolescent Oncology, Institut Gustave-Roussy, Villejuif, France
| | - Eric Bouffet
- Neuro-oncology Program, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Steven C. Clifford
- Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle upon Tyne, United Kingdom
| |
Collapse
|
13
|
Mushtaq N, Mustansir F, Minhas K, Usman S, Qureshi BM, Mubarak F, Bari E, Enam SA, Laghari AA, Javed G, Shamim S, Darbar A, Abbasi AN, Kirmani S, Resham S, Bilal A, Hamid SA, Zia N, Shaheen N, Wali R, Ghafoor T, Imam U, Maaz AUR, Khan S, Laperriere N, Desbrandes F, Dirks P, Drake J, Huang A, Tabori U, Hawkins C, Bartels U, Ramaswamy V, Bouffet E. Building the ecosystem for pediatric neuro-oncology care in Pakistan: Results of a 7-year long twinning program between Canada and Pakistan. Pediatr Blood Cancer 2022; 69:e29726. [PMID: 35484912 DOI: 10.1002/pbc.29726] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 02/23/2022] [Accepted: 03/02/2022] [Indexed: 11/10/2022]
Abstract
BACKGROUND Low- and middle-income countries sustain the majority of pediatric cancer burden, with significantly poorer survival rates compared to high-income countries. Collaboration between institutions in low- and middle-income countries and high-income countries is one of the ways to improve cancer outcomes. METHODS Patient characteristics and effects of a pediatric neuro-oncology twinning program between the Hospital for Sick Children in Toronto, Canada and several hospitals in Karachi, Pakistan over 7 years are described in this article. RESULTS A total of 460 patients were included in the study. The most common primary central nervous system tumors were low-grade gliomas (26.7%), followed by medulloblastomas (18%), high-grade gliomas (15%), ependymomas (11%), and craniopharyngiomas (11.7%). Changes to the proposed management plans were made in consultation with expert physicians from the Hospital for Sick Children in Toronto, Canada. On average, 24% of the discussed cases required a change in the original management plan over the course of the twinning program. However, a decreasing trend in change in management plans was observed, from 36% during the first 3.5 years to 16% in the last 3 years. This program also led to the launch of a national pediatric neuro-oncology telemedicine program in Pakistan. CONCLUSIONS Multidisciplinary and collaborative efforts by experts from across the world have aided in the correct diagnosis and treatment of children with brain tumors and helped establish local treatment protocols. This experience may be a model for other low- and middle-income countries that are planning on creating similar programs.
Collapse
Affiliation(s)
- Naureen Mushtaq
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | - Fatima Mustansir
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | - Khurram Minhas
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | - Sadia Usman
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | - Bilal Mazhar Qureshi
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | - Fatima Mubarak
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | - Ehsan Bari
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | - Syed Ather Enam
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | - Altaf Ali Laghari
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | - Gohar Javed
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | - Shahzad Shamim
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | - Aneela Darbar
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | - Ahmed Nadeem Abbasi
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | - Salman Kirmani
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | - Shahazadi Resham
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | - Afia Bilal
- Division of Pediatric Oncology, Department of Oncology, Aga Khan University, Karachi, Pakistan
| | | | - Nida Zia
- Indus Children Cancer Hospital, Karachi, Pakistan
| | - Najma Shaheen
- Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan
| | - Rabia Wali
- Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan
| | | | - Uzma Imam
- National Institute of Child Health, Karachi, Pakistan
| | | | - Sara Khan
- The Hospital for Sick Children, Toronto, Canada
| | | | | | - Peter Dirks
- The Hospital for Sick Children, Toronto, Canada
| | - James Drake
- The Hospital for Sick Children, Toronto, Canada
| | - Annie Huang
- The Hospital for Sick Children, Toronto, Canada
| | - Uri Tabori
- The Hospital for Sick Children, Toronto, Canada
| | | | - Ute Bartels
- The Hospital for Sick Children, Toronto, Canada
| | | | | |
Collapse
|
14
|
Khader J, Glicksman RM, Mheid S, Mansour A, Giuliani ME, Gospodarowicz M, Almousa A, Abdel-Razeq H, Rodin D. Enhancing International Cancer Organization Collaborations: King Hussein Cancer Center and Princess Margaret Cancer Centre Model for Collaboration. JOURNAL OF CANCER EDUCATION : THE OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER EDUCATION 2022; 37:763-769. [PMID: 32926325 DOI: 10.1007/s13187-020-01878-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 09/09/2020] [Indexed: 06/11/2023]
Abstract
Collaborative partnerships, which link two health organizations with shared characteristics to achieve common goals and to improve healthcare quality, are becoming increasingly common in oncology. The purpose of this study is to review the collaboration between King Hussein Cancer Center (KHCC) and Princess Margaret Cancer Centre (PM). The context, input, process, and product (CIPP) model, a quasi-experimental form of program evaluation, has been applied to the KHCC-PM collaboration. This model is well suited to evaluate complex collaborations as it does not assume linear relationships. Data sources include stakeholders' judgements of the collaboration, assessment of achievements, and informal interviews with key participants involved in the program. KHCC and PM are recognized as high-caliber comprehensive cancer centers, with a common goal of delivering high-quality care to patients. Through personal relationships among faculty in the centers and the perceived opportunities for mutual benefit, KHCC and PM signed a memorandum of understanding in 2013 to enter into a formal partnership. This partnership has been an evolving process that started with collaboration on education and grew to include clinical care. Research is an area for potential future collaboration. Enabling factors in the collaboration include dedication of individuals involved, trusting relationships amongst faculty, and the reciprocal nature of the relationship. Challenges have been financial, competing interests, and the absence of a successful collaborative model to follow. The KHCC and PM collaboration has been successful. A strategic plan is being developed and followed to guide areas of expansion.
Collapse
Affiliation(s)
- Jamal Khader
- Department of Radiation Oncology, King Hussein Cancer Center, P.O Box 1269, Amman, 11941, Jordan
| | - Rachel M Glicksman
- Department of Radiation Oncology, University of Toronto, Toronto, Canada
| | - Sara Mheid
- Department of Radiation Oncology, King Hussein Cancer Center, P.O Box 1269, Amman, 11941, Jordan.
| | - Asem Mansour
- Department of Radiology, King Hussein Cancer Center, Amman, Jordan
| | - Meredith E Giuliani
- Department of Radiation Oncology, University of Toronto, Toronto, Canada
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Mary Gospodarowicz
- Department of Radiation Oncology, University of Toronto, Toronto, Canada
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Abdelatif Almousa
- Department of Radiation Oncology, King Hussein Cancer Center, P.O Box 1269, Amman, 11941, Jordan
| | | | - Danielle Rodin
- Department of Radiation Oncology, University of Toronto, Toronto, Canada
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| |
Collapse
|
15
|
Ngwa W, Addai BW, Adewole I, Ainsworth V, Alaro J, Alatise OI, Ali Z, Anderson BO, Anorlu R, Avery S, Barango P, Bih N, Booth CM, Brawley OW, Dangou JM, Denny L, Dent J, Elmore SNC, Elzawawy A, Gashumba D, Geel J, Graef K, Gupta S, Gueye SM, Hammad N, Hessissen L, Ilbawi AM, Kambugu J, Kozlakidis Z, Manga S, Maree L, Mohammed SI, Msadabwe S, Mutebi M, Nakaganda A, Ndlovu N, Ndoh K, Ndumbalo J, Ngoma M, Ngoma T, Ntizimira C, Rebbeck TR, Renner L, Romanoff A, Rubagumya F, Sayed S, Sud S, Simonds H, Sullivan R, Swanson W, Vanderpuye V, Wiafe B, Kerr D. Cancer in sub-Saharan Africa: a Lancet Oncology Commission. Lancet Oncol 2022; 23:e251-e312. [PMID: 35550267 PMCID: PMC9393090 DOI: 10.1016/s1470-2045(21)00720-8] [Citation(s) in RCA: 141] [Impact Index Per Article: 47.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2021] [Revised: 12/02/2021] [Accepted: 12/06/2021] [Indexed: 01/13/2023]
Abstract
In sub-Saharan Africa (SSA), urgent action is needed to curb a growing crisis in cancer incidence and mortality. Without rapid interventions, data estimates show a major increase in cancer mortality from 520 348 in 2020 to about 1 million deaths per year by 2030. Here, we detail the state of cancer in SSA, recommend key actions on the basis of analysis, and highlight case studies and successful models that can be emulated, adapted, or improved across the region to reduce the growing cancer crises. Recommended actions begin with the need to develop or update national cancer control plans in each country. Plans must include childhood cancer plans, managing comorbidities such as HIV and malnutrition, a reliable and predictable supply of medication, and the provision of psychosocial, supportive, and palliative care. Plans should also engage traditional, complementary, and alternative medical practices employed by more than 80% of SSA populations and pathways to reduce missed diagnoses and late referrals. More substantial investment is needed in developing cancer registries and cancer diagnostics for core cancer tests. We show that investments in, and increased adoption of, some approaches used during the COVID-19 pandemic, such as hypofractionated radiotherapy and telehealth, can substantially increase access to cancer care in Africa, accelerate cancer prevention and control efforts, increase survival, and save billions of US dollars over the next decade. The involvement of African First Ladies in cancer prevention efforts represents one practical approach that should be amplified across SSA. Moreover, investments in workforce training are crucial to prevent millions of avoidable deaths by 2030. We present a framework that can be used to strategically plan cancer research enhancement in SSA, with investments in research that can produce a return on investment and help drive policy and effective collaborations. Expansion of universal health coverage to incorporate cancer into essential benefits packages is also vital. Implementation of the recommended actions in this Commission will be crucial for reducing the growing cancer crises in SSA and achieving political commitments to the UN Sustainable Development Goals to reduce premature mortality from non-communicable diseases by a third by 2030.
Collapse
Affiliation(s)
- Wilfred Ngwa
- Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, MD, USA; Department of Information and Sciences, ICT University, Yaoundé, Cameroon.
| | - Beatrice W Addai
- Breast Care International, Peace and Love Hospital, Kumasi, Ghana
| | - Isaac Adewole
- College of Medicine, University of Ibadan, Ibadan, Nigeria
| | - Victoria Ainsworth
- Department of Physics and Applied Physics, University of Massachusetts Lowell, Lowell, MA, USA
| | - James Alaro
- National Cancer Institute, National Institute of Health, Bethesda, MD, USA
| | | | - Zipporah Ali
- Kenya Hospices and Palliative Care Association, Nairobi, Kenya
| | - Benjamin O Anderson
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Non-communicable Diseases, WHO, Geneva, Switzerland
| | - Rose Anorlu
- Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Lagos University Teaching Hospital, Lagos, Nigeria
| | - Stephen Avery
- Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Prebo Barango
- WHO, Regional Office for Africa, Brazzaville, Republic of the Congo
| | - Noella Bih
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - Christopher M Booth
- Division of Cancer Care and Epidemiology, Cancer Research Institute, Queen's University, Kingston, ON, Canada
| | - Otis W Brawley
- Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, MD, USA; Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
| | | | - Lynette Denny
- Department of Obstetrics and Gynaecology, University of Cape Town, Cape Town, South Africa; South African Medical Research Council, Gynaecological Cancer Research Centre, Tygerberg, South Africa
| | | | - Shekinah N C Elmore
- Department of Radiation Oncology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA
| | - Ahmed Elzawawy
- Department of Clinical Oncology, Suez Canal University, Ismailia, Egypt
| | | | - Jennifer Geel
- Division of Paediatric Haematology and Oncology, Faculty of Health Sciences, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa
| | - Katy Graef
- BIO Ventures for Global Health, Seattle, WA, USA
| | - Sumit Gupta
- Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
| | | | - Nazik Hammad
- Department of Oncology, Queen's University, Kingston, ON, Canada
| | - Laila Hessissen
- Pediatric Oncology Department, Pediatric Teaching Hospital, Rabat, Morocco
| | - Andre M Ilbawi
- Department of Non-communicable Diseases, WHO, Geneva, Switzerland
| | - Joyce Kambugu
- Department of Pediatrics, Uganda Cancer Institute, Kampala, Uganda
| | - Zisis Kozlakidis
- Laboratory Services and Biobank Group, International Agency for Research on Cancer, WHO, Lyon, France
| | - Simon Manga
- Cameroon Baptist Convention Health Services, Bamenda, Cameroon
| | - Lize Maree
- Department of Nursing Education, University of the Witwatersrand, Johannesburg, South Africa
| | - Sulma I Mohammed
- Department of Comparative Pathobiology, Center for Cancer Research, Purdue University, West Lafayette, IN, USA
| | - Susan Msadabwe
- Department of Radiation Therapy, Cancer Diseases Hospital, Lusaka, Zambia
| | - Miriam Mutebi
- Department of Surgery, Aga Khan University Hospital, Nairobi, Kenya
| | | | - Ntokozo Ndlovu
- Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe
| | - Kingsley Ndoh
- Department of Global Health, University of Washington, Seattle, WA, USA
| | | | - Mamsau Ngoma
- Ocean Road Cancer Institute, Dar es Salaam, Tanzania
| | - Twalib Ngoma
- Department of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
| | | | - Timothy R Rebbeck
- Dana-Farber Cancer Institute, Harvard T H Chan School of Public Health, Boston, MA, USA
| | - Lorna Renner
- Department of Paediatrics, University of Ghana School of Medicine and Dentistry, Accra, Ghana
| | - Anya Romanoff
- Department of Health System Design and Global Health, Icahn School of Medicine, The Mount Sinai Hospital, New York, NY, USA
| | - Fidel Rubagumya
- Department of Oncology, Rwanda Military Hospital, Kigali, Rwanda; University of Global Health Equity, Kigali, Rwanda
| | - Shahin Sayed
- Department of Pathology, Aga Khan University Hospital, Nairobi, Kenya
| | - Shivani Sud
- Department of Radiation Oncology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA
| | - Hannah Simonds
- Division of Radiation Oncology, Tygerberg Hospital and University of Stellenbosch, Stellenbosch, South Africa
| | | | - William Swanson
- Department of Physics and Applied Physics, Dana-Farber Cancer Institute, University of Massachusetts Lowell, Lowell, MA, USA
| | - Verna Vanderpuye
- National Centre for Radiotherapy, Oncology, and Nuclear Medicine, Korle Bu Teaching Hospital, Accra, Ghana
| | | | - David Kerr
- Radcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK
| |
Collapse
|
16
|
Barrios C, Sánchez-Vanegas G, Villarreal-Garza C, Ossa A, Lombana MA, Monterrosa-Blanco A, Ferrigno AS, Castro CA. Barriers and facilitators to provide multidisciplinary care for breast cancer patients in five Latin American countries: A descriptive-interpretative qualitative study. LANCET REGIONAL HEALTH. AMERICAS 2022; 11:100254. [PMID: 36778924 PMCID: PMC9904076 DOI: 10.1016/j.lana.2022.100254] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Background Multidisciplinary care (MDC) remains a cornerstone for breast cancer management as it is associated with improved quality of care and patient outcomes. However, the adoption of MDC practice is heterogeneous and has been poorly explored in Latin America. The objective was to describe barriers and possible facilitators for providing MDC to breast cancer patients in five Latin American countries. Methods A panel of experts with an active clinical practice in Bolivia, Colombia, Ecuador, Mexico, and Uruguay was convened to identify barriers and facilitators to MDC. This study is a qualitative synthesis of a structured discussion regarding the state of MDC in the setting of breast cancer. Findings Experts recognized that most oncology practices in Latin America do not apply a multidisciplinary approach for breast cancer patients. Predominant barriers for MDC are fragmentation of health services, being understaffed, inadequate infrastructure, and geographic disparities. Access to MDC varies widely in the region, with significant heterogeneity documented within countries. MDC practice was described as being more common in the private sector in Ecuador and Uruguay, while it is more widely implemented in public institutions of Colombia and Bolivia. Interpretation Establishing quality MDC remains a challenge for oncology practices in Latin America. Addressing regional issues and identifying specific local needs is warranted to encourage the adoption of an effective multidisciplinary approach and, consequently, improve clinical outcomes. Active involvement of all stakeholders is required to build locally solutions and should involve institutions, health professionals, and patients. Funding Research was funded by Productos Roche S.A.
Collapse
Affiliation(s)
- Carlos Barrios
- Oncoclinicas Group, Oncology Research Center, Hospital São Lucas, PUCRS Latin-American Cooperative Oncology Group (LACOG), Rio Grande do Sul, RS, Brazil
| | - Guillermo Sánchez-Vanegas
- Soluciones Integrales Para la Investigación y la Educación en Salud – SIIES Consultores, Cr 45ª #106ª-20, Bogotá, Cundinamarca, Colombia,Fundación Universtiaria de Ciencias de la Salud-FUCS, Bogotá, Colombia.,Corresponding author.
| | - Cynthia Villarreal-Garza
- Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza García, Nuevo León, México
| | - Andrés Ossa
- Coordinator Breast Cancer Department Hospital General de Medellín, Medellín, Antioquia, Colombia
| | - Milton A. Lombana
- Scientific Medical Head at Comprehensive Cancer Center, Clinica de Occidente, Cali, Valle del Cauca, Colombia
| | - Angélica Monterrosa-Blanco
- Soluciones Integrales Para la Investigación y la Educación en Salud – SIIES Consultores, Cr 45ª #106ª-20, Bogotá, Cundinamarca, Colombia
| | - Ana S. Ferrigno
- Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza García, Nuevo León, México
| | - Carlos Alberto Castro
- Soluciones Integrales Para la Investigación y la Educación en Salud – SIIES Consultores, Cr 45ª #106ª-20, Bogotá, Cundinamarca, Colombia,Fundación Universtiaria de Ciencias de la Salud-FUCS, Bogotá, Colombia
| |
Collapse
|
17
|
Lee NK, Stewart MA, Dymond JS, Lewis SL. An Implementation Strategy to Develop Sustainable Surveillance Activities Through Adoption of a Target Operating Model. Front Public Health 2022; 10:871114. [PMID: 35462851 PMCID: PMC9019047 DOI: 10.3389/fpubh.2022.871114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Accepted: 03/14/2022] [Indexed: 11/13/2022] Open
Abstract
The increasing threat of emerging and re-emerging pathogens calls for a shared vision toward developing and maintaining global surveillance mechanisms to enable rapid characterization of pathogens, a foundational requirement for effective outbreak response. Efforts establishing new surveillance programs in low- and middle-income countries (LMICs) have repeatedly led to siloed systems that prove unsustainable or ineffective due to narrowly focused approaches, competing priorities, or lack of resourcing. Barriers inherent to LMICs, such as resource limitations, workforce strain, unreliable supply chains, and lack of enduring champions exacerbate implementation and sustainability challenges. In order to improve adoption and endurance of new surveillance programs, more effective design and implementation of programs is needed to adequately reflect stakeholder needs and simultaneously support population-level disease monitoring and clinical decision-making across a range of chronic and acute health issues. At the heart of this cross-sectorial integration between clinical care and public health initiatives are emerging technologies and data modalities, including sequencing data. In this prospective, we propose an implementation strategy for genomics-based surveillance initiatives in LMICs founded on the use of a target operating model. Adoption of a target operating model for the design and implementation of genomic surveillance programs will ensure programs are agile, relevant, and unified across diverse stakeholder communities, thereby increasing their overall impact and sustainability.
Collapse
Affiliation(s)
- Natalie K. Lee
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD, United States
| | | | | | | |
Collapse
|
18
|
Hopp AM, Tetzlaff JE, Kopidlansky K, Leventaki V, Parsons LN, Bone K, Drendel HM, Sreynich K, Lyvannak S, Heng S, Chanpheaktra N, Putchhat H, Khauv P, Camitta BM, Jarzembowski JA. It Takes a Village. Am J Clin Pathol 2022; 158:81-95. [PMID: 35050350 DOI: 10.1093/ajcp/aqab220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Accepted: 12/20/2021] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVES Partnerships between low- to middle-income countries (LMICs) and high-income countries (HICs) is one strategy to mitigate observed health disparities. Cambodia's Angkor Hospital for Children (AHC), an LMIC institution, faces shortages in health care resources, including pathology services. A partnership was created with Children's Wisconsin (CW), an HIC hospital, including provision of pathology services. We describe our established pathology workflow, examine cases seen in AHC patients, and evaluate the impact of CW's interpretations. METHODS AHC provides clinical history and impression and ships samples to CW, which processes the samples, and pathologists provide interpretations, sending reports electronically to AHC. For analysis, final diagnoses were considered "concordant," "refined," or "discordant" based on agreement with the clinical impression. Cases were also classified as "did not change management" or "changed management" based on how CW interpretation affected clinical management. RESULTS We included 347 specimens (177 malignant, 146 benign, 24 insufficient for diagnosis). Of these cases, 31% were discordant and 44% of cases with clinical follow-up had a change in management with CW interpretation. CONCLUSIONS Inclusion of pathology services in LMIC-HIC partnerships is crucial for resolving health disparities between the institutions involved. The described partnership and established pathology workflow can be adapted to the needs and resources of many institutions.
Collapse
Affiliation(s)
- Amanda M Hopp
- Department of Pathology, Children’s Wisconsin, Milwaukee, WI, USA
- Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Julie E Tetzlaff
- Department of Pathology, Children’s Wisconsin, Milwaukee, WI, USA
- Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Kyle Kopidlansky
- Department of Pathology, Children’s Wisconsin, Milwaukee, WI, USA
| | - Vasiliki Leventaki
- Department of Pathology, Children’s Wisconsin, Milwaukee, WI, USA
- Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Lauren N Parsons
- Department of Pathology, Children’s Wisconsin, Milwaukee, WI, USA
- Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Kathleen Bone
- Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Holli M Drendel
- Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
| | | | - Sam Lyvannak
- Angkor Hospital for Children, Siem Reap, Cambodia
| | - Sing Heng
- Angkor Hospital for Children, Siem Reap, Cambodia
| | | | | | - Phara Khauv
- Angkor Hospital for Children, Siem Reap, Cambodia
| | - Bruce M Camitta
- Department of Hematology, Oncology, and Blood and Marrow Transplant, Children’s Wisconsin, Milwaukee, WI, USA
| | - Jason A Jarzembowski
- Department of Pathology, Children’s Wisconsin, Milwaukee, WI, USA
- Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA
| |
Collapse
|
19
|
Nguyen MC, Nguyen V, Le H, Nguyen DV, Nguyen ML, Hermiston ML, Bui CB, Loh AHP. Subcutaneous panniculitis-like T-cell lymphomas with homozygous inheritance of HAVCR2 mutations in Vietnamese pedigrees. Pediatr Blood Cancer 2021; 68:e29292. [PMID: 34398505 DOI: 10.1002/pbc.29292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 07/06/2021] [Accepted: 08/02/2021] [Indexed: 11/08/2022]
Affiliation(s)
| | - Vy Nguyen
- DNA Medical Technology, Ho Chi Minh City, Vietnam
| | - Hoa Le
- Children Hospital 2, Ho Chi Minh City, Vietnam
| | | | - Mai-Lan Nguyen
- University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam
| | - Michelle L Hermiston
- Department of Pediatrics, University of California San Francisco, San Francisco, California, USA.,Southeast Asia Pediatric Hematology Oncology (SEAPHO), University of California San Francisco, San Francisco, California, USA
| | - Chi-Bao Bui
- City Children's Hospital, Ho Chi Minh City, Vietnam.,School of Medicine, Vietnam National University, Ho Chi Minh City, Vietnam
| | - Amos Hong Pheng Loh
- VIVA KKH Paediatric Brain and Solid Tumour Programme, KK Womens' and Children's Hospital, Singapore.,SingHealth Duke NUS Global Health Institute, Duke NUS Medical School, Singapore
| |
Collapse
|
20
|
Stanway S, Lodge M, Sullivan R, Diprose K, Young AM, Crisp N, Lewis P, Eden T, Aggarwal A, Nadin A, Chinegwundoh F, Sirohi B, Byrne G, Cowan R. The UK's contribution to cancer control in low-income and middle-income countries. Lancet Oncol 2021; 22:e410-e418. [PMID: 34478677 DOI: 10.1016/s1470-2045(21)00380-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2021] [Revised: 06/04/2021] [Accepted: 06/17/2021] [Indexed: 11/24/2022]
Abstract
Cancer mortality rates in low-income and middle-income countries (LMICs) are unacceptably high, requiring both collaborative global effort and in-country solutions. Experience has shown that working together in policy, clinical practice, education, training, and research leads to bidirectional benefit for LMICs and high-income countries. For over 60 years, the UK National Health Service has benefited from recruitment from LMICs, providing the UK with a rich diaspora of trained health-care professionals with links to LMICs. A grassroots drive to engage with partners in LMICs within the UK has grown from the National Health Service, UK academia, and other organisations. This drive has generated a model that rests on two structures: London Global Cancer Week and the UK Global Cancer Network, providing a high-value foundation for international discussion and collaboration. Starting with a historical perspective, this Series paper describes the UK landscape and offers a potential plan for the future UK's contribution to global cancer control. We also discuss the opportunities and challenges facing UK partnerships with LMICs in cancer control. The UK should harness the skills, insights, and political will from all partners to make real progress.
Collapse
Affiliation(s)
| | - Mark Lodge
- UK Global Cancer Network, Manchester, UK; International Network for Cancer Treatment and Research, Oxford, UK
| | | | | | - Annie M Young
- UK Global Cancer Network, Manchester, UK; Warwick Medical School, University of Warwick, Coventry, UK
| | - Nigel Crisp
- House of Lords, Houses of Parliament, London, UK
| | - Philippa Lewis
- Department of Clinical Oncology, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
| | - Tim Eden
- World Child Cancer, London, UK; School of Medical Sciences, University of Manchester, Manchester, UK
| | - Ajay Aggarwal
- Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK
| | | | | | | | - Ged Byrne
- Health Education England Global Engagement, London, UK; Department of Surgery, Manchester NHS Foundation Trust, Manchester, UK
| | - Richard Cowan
- UK Global Cancer Network, Manchester, UK; School of Medical Sciences, University of Manchester, Manchester, UK; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK
| |
Collapse
|
21
|
Afungchwi GM, Kruger M, Wharin PD, Bardin R, Kouya FN, Hesseling PB. The Evolution of a Hospital-Based Cancer Registry in Northwest Cameroon from 2004 to 2015. J Trop Pediatr 2021; 67:5918207. [PMID: 33020840 DOI: 10.1093/tropej/fmaa038] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Effective cancer registration is required for the development of cancer management policies, but is often deficient in the developing world. In 2008 cancer registration was set up Banso Baptist Hospital and Mbingo Baptist Hospital in the Northwest region of Cameroon, using the Pediatric Oncology Networked Database (POND). The objective of this study was to analyze the POND registry data for patients with cancer aged 0-15 years for the period 2004-15. A total of 1029 malignancies were recorded in children 0-15 years in the study period. The male-to-female ratio was 1.4:1. The median age at diagnosis was 7.22 years. The most common malignancies were lymphomas followed by nephroblastoma, retinoblastoma, rhabdomyosarcoma and Kaposi sarcoma. There were more Burkitt lymphomas cases between 2004 and 2009 than between 2010 and 2015, while the number of cases rose for other diagnoses like retinoblastoma and nephroblastoma. This report has demonstrated how pediatric oncology registration can be implemented, improved and sustained in a low- and middle-income country setting with limited resources. Using the data, these hospitals can improve their treatment planning and ensure the availability of essential chemotherapy for childhood cancers.
Collapse
Affiliation(s)
- Glenn M Afungchwi
- Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, 8000, South Africa.,Department of Paediatric Oncology, Mbingo Baptist Hospital, Mbingo, 00237, Cameroon
| | - Mariana Kruger
- Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, 8000, South Africa
| | - Paul D Wharin
- Beryl Thyer Memorial Africa Trust, 15 Warkton, 9XF, UK
| | - Richard Bardin
- Department of Paediatric Oncology, Mbingo Baptist Hospital, Mbingo, 00237, Cameroon
| | - Francine N Kouya
- Department of Paediatric Oncology, Mbingo Baptist Hospital, Mbingo, 00237, Cameroon
| | - Peter B Hesseling
- Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, 8000, South Africa
| |
Collapse
|
22
|
Hricak H, Abdel-Wahab M, Atun R, Lette MM, Paez D, Brink JA, Donoso-Bach L, Frija G, Hierath M, Holmberg O, Khong PL, Lewis JS, McGinty G, Oyen WJG, Shulman LN, Ward ZJ, Scott AM. Medical imaging and nuclear medicine: a Lancet Oncology Commission. Lancet Oncol 2021; 22:e136-e172. [PMID: 33676609 PMCID: PMC8444235 DOI: 10.1016/s1470-2045(20)30751-8] [Citation(s) in RCA: 154] [Impact Index Per Article: 38.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2020] [Revised: 12/04/2020] [Accepted: 12/07/2020] [Indexed: 12/13/2022]
Abstract
The diagnosis and treatment of patients with cancer requires access to imaging to ensure accurate management decisions and optimal outcomes. Our global assessment of imaging and nuclear medicine resources identified substantial shortages in equipment and workforce, particularly in low-income and middle-income countries (LMICs). A microsimulation model of 11 cancers showed that the scale-up of imaging would avert 3·2% (2·46 million) of all 76·0 million deaths caused by the modelled cancers worldwide between 2020 and 2030, saving 54·92 million life-years. A comprehensive scale-up of imaging, treatment, and care quality would avert 9·55 million (12·5%) of all cancer deaths caused by the modelled cancers worldwide, saving 232·30 million life-years. Scale-up of imaging would cost US$6·84 billion in 2020-30 but yield lifetime productivity gains of $1·23 trillion worldwide, a net return of $179·19 per $1 invested. Combining the scale-up of imaging, treatment, and quality of care would provide a net benefit of $2·66 trillion and a net return of $12·43 per $1 invested. With the use of a conservative approach regarding human capital, the scale-up of imaging alone would provide a net benefit of $209·46 billion and net return of $31·61 per $1 invested. With comprehensive scale-up, the worldwide net benefit using the human capital approach is $340·42 billion and the return per dollar invested is $2·46. These improved health and economic outcomes hold true across all geographical regions. We propose actions and investments that would enhance access to imaging equipment, workforce capacity, digital technology, radiopharmaceuticals, and research and training programmes in LMICs, to produce massive health and economic benefits and reduce the burden of cancer globally.
Collapse
Affiliation(s)
- Hedvig Hricak
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiology, Weill Cornell Medical College, New York, NY, USA.
| | - May Abdel-Wahab
- International Atomic Energy Agency, Division of Human Health, Vienna, Austria; Radiation Oncology, National Cancer Institute, Cairo University, Cairo, Egypt; Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Rifat Atun
- Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, USA; Department of Global Health and Social Medicine, Harvard Medical School, Harvard University, Boston, MA, USA
| | | | - Diana Paez
- International Atomic Energy Agency, Division of Human Health, Vienna, Austria
| | - James A Brink
- Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Harvard University, Boston, MA, USA
| | - Lluís Donoso-Bach
- Department of Medical Imaging, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain
| | | | | | - Ola Holmberg
- Radiation Protection of Patients Unit, International Atomic Energy Agency, Vienna, Austria
| | - Pek-Lan Khong
- Department of Diagnostic Radiology, University of Hong Kong, Hong Kong Special Administrative Region, China
| | - Jason S Lewis
- Department of Radiology and Molecular Pharmacology Programme, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Departments of Pharmacology and Radiology, Weill Cornell Medical College, New York, NY, USA
| | - Geraldine McGinty
- Departments of Radiology and Population Science, Weill Cornell Medical College, New York, NY, USA; American College of Radiology, Reston, VA, USA
| | - Wim J G Oyen
- Department of Biomedical Sciences and Humanitas Clinical and Research Centre, Department of Nuclear Medicine, Humanitas University, Milan, Italy; Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, Netherlands; Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, Netherlands
| | - Lawrence N Shulman
- Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | - Zachary J Ward
- Center for Health Decision Science, Harvard TH Chan School of Public Health, Boston, MA, USA
| | - Andrew M Scott
- Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia
| |
Collapse
|
23
|
Kakkar S, Anand V, Mahajan M, Sandhu P, Rana M, Singh K, Kaur A, Kaur I, Jindal A, Gupta H, Bagai P. Stakeholder collaboration: Government, private sector and non-governmental organizations can build pediatric oncology services in India. PEDIATRIC HEMATOLOGY ONCOLOGY JOURNAL 2021. [DOI: 10.1016/j.phoj.2020.11.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
24
|
Kanwar VS, Schwartz KR, Salifu N, Abdelfattah AM, Anim B, Cayrol J, Sniderman E, Eden T. The role of twinning in sustainable care for children with cancer: A TIPPing point? SIOP PODC Working Group on Twinning, Collaboration, and Support. Pediatr Blood Cancer 2020; 67:e28667. [PMID: 32827347 DOI: 10.1002/pbc.28667] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/14/2020] [Revised: 07/18/2020] [Accepted: 08/06/2020] [Indexed: 02/06/2023]
Abstract
With the World Health Organization (WHO) Global Initiative for Childhood Cancer, there is renewed interest in sustainable interventions to improve childhood cancer care in low-/middle-income countries (LMICs). Practitioners in LMICs have traditionally practiced "twinning," i.e., targeted international pediatric oncology partnerships (TIPPs) between one or more institutions in a high-income country (HIC) and an LMIC, to improve care for children with cancer in the latter. The International Society of Paediatric Oncology Committee for Paediatric Oncology in Developing Countries Working Group on Twinning, Collaboration, and Support reviewed guidelines from https://cancerpointe.com and the current literature, gathered input from practitioners in LMICs, and in this article discuss the role of TIPPs in the WHO initiative.
Collapse
Affiliation(s)
- Vikramjit S Kanwar
- QURE Center for Complete Care, Ahmedabad, India and Albany Medical College, New York
| | | | | | | | - Bernard Anim
- Harvard School of Public Health, Boston, Massachusetts
| | - Julie Cayrol
- Royal Children's Hospital, University of Melbourne, Australia
| | | | - Tim Eden
- World Child Cancer and University of Manchester, Manchester, UK
| |
Collapse
|
25
|
Childhood cancer in Latin America: from detection to palliative care and survivorship. Cancer Epidemiol 2020; 71:101837. [PMID: 33121936 DOI: 10.1016/j.canep.2020.101837] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2020] [Revised: 09/29/2020] [Accepted: 10/05/2020] [Indexed: 12/12/2022]
Abstract
BACKGROUND Treatment options for childhood cancer have improved substantially, although in many low- and middle-income countries survival is lagging behind. Integral childhood cancer care involves the whole spectrum from detection and diagnosis to palliative and survivorship care. METHODS Based on a literature review and expert opinions, we summarized current practice and recommendations on the following aspects of childhood cancer in Latin America: diagnostic processes and time to diagnosis, stage at diagnosis, treatments and complications, survivorship programs and palliative care and end-of-life services. RESULTS Latin America is a huge and heterogeneous continent. Identified barriers show similar problems between countries, both logistically (time and distance to centers, treatment interruptions) and financially (cost of care, cost of absence from work). Governmental actions in several countries improved the survival of children with cancer, but difficulties persist in timely diagnosis and providing adequate treatment to all childhood cancer patients in institutions with complete infrastructure. Treatment abandonment is still common, although the situation is improving. Cancer care in the region has mostly focused on acute treatment of the disease and has not adequately considered palliative and end-of-life care and monitoring of survivors. CONCLUSIONS Decentralizing diagnostic activities and centralizing specialized treatment will remain necessary; measures to facilitate logistics and costs of transportation of the child and caretakers should be implemented. Twinning actions with specialized centers in high income countries for help in diagnosis, treatment and education of professionals and family members have been shown to work. Palliative and end-of-life care as well as childhood cancer survivorship plans are needed.
Collapse
|
26
|
Sruamsiri R, Ferrario A, Ross-Degnan D, Denburg AE, Frazier AL, Gupta S, Ward ZJ, Yeh JM, Wagner AK. What are the volume and budget needs to provide chemotherapy to all children with acute lymphoblastic leukaemia in Thailand? Development and application of an estimation tool. BMJ Open 2020; 10:e041901. [PMID: 33109678 PMCID: PMC7592266 DOI: 10.1136/bmjopen-2020-041901] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
OBJECTIVE Insufficient access to anticancer medicines may contribute to the wide survival differences of children with cancers across the globe. We developed a tool to estimate the volume of medicines and budget requirements to provide chemotherapy to children with acute lymphoblastic leukaemia (ALL). DESIGN Development and application of an estimation tool. SETTING Paediatric oncology hospital departments in Thailand. PARTICIPANTS 318 children aged 0-14 years diagnosed with ALL and 215 children with undiagnosed ALL. INTERVENTIONS Estimates of volume and budget requirements for administering a full course of chemotherapy for ALL and a further course for children who relapse, according to National Treatment Guidelines. PRIMARY AND SECONDARY OUTCOME MEASURES Primary outcome measures were the volume (mg) and cost (US$) of medicines needed to treat children with ALL. For medicines whose main indication is paediatric ALL (asparaginase and 6-mercaptopurine), we estimated the difference between volume needed and actual sales in 2017 (secondary outcome). RESULTS Ten anticancer medicines and four chemoprotective agents are needed for the treatment of paediatric ALL according to the Thai treatment guidelines. Of these 14 medicines, 13 are included in the WHO essential medicines list for children. All are available as generics. We estimated that essential chemotherapy and chemoprotective agents to treat all children diagnosed with ALL in Thailand in 2017 would cost US$ 814 952 (US$ 1 365 422 for diagnosed and undiagnosed children), which corresponds to 0.005% (0.008%) of the country's total health expenditure. The volumes of asparaginase and 6-mercaptopurine available on the Thai market in 2017 were more than sufficient (2.3 and 1.5 times the amounts needed, respectively) to treat all children diagnosed with ALL. CONCLUSIONS Procuring sufficient quantities of essential medicines to treat children with ALL requires relatively modest resources. Medicine cost should not be a major barrier to ALL treatment in similar settings.
Collapse
Affiliation(s)
- Rosarin Sruamsiri
- Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Tha Pho, Phitsanulok, Thailand
| | - Alessandra Ferrario
- Department of Population Medicine, Division of Health Policy and Insurance Research, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA
| | - Dennis Ross-Degnan
- Department of Population Medicine, Division of Health Policy and Insurance Research, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA
| | - Avram E Denburg
- Unit for Policy and Economic Research in Childhood Cancer, Centre for Global Child Health, The Hospital for Sick Children, Toronto, Ontario, Canada
- Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada
- Child Health Evaluative Sciences, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, Ontario, Canada
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
| | - A Lindsay Frazier
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA
| | - Sumit Gupta
- Unit for Policy and Economic Research in Childhood Cancer, Centre for Global Child Health, The Hospital for Sick Children, Toronto, Ontario, Canada
- Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada
- Child Health Evaluative Sciences, Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children, Toronto, Ontario, Canada
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
| | - Zachary J Ward
- Center for Health Decision Science, Harvard University T H Chan School of Public Health, Boston, Massachusetts, USA
| | - Jennifer M Yeh
- Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA
- Division of General Pediatrics, Boston Children's Hospital, Boston, Massachusetts, United States
| | - Anita Katharina Wagner
- Department of Population Medicine, Division of Health Policy and Insurance Research, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA
| |
Collapse
|
27
|
Faizan M, Caniza MA, Anwar S, Kashif RUA, Saleem R, Javed H, Zafar A, Taj MM, Hameed A, Homsi M, Rathore AW, Sadiq M, Gonzalez M, Zaidi A. Infection Prevention and Control Measures at the Children Hospital Lahore: A My Child Matters Collaborative Project. JCO Glob Oncol 2020; 6:1540-1545. [PMID: 33064627 PMCID: PMC7605375 DOI: 10.1200/go.20.00403] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
PURPOSE Infection prevention among children with cancer is a major challenge at Children Hospital Lahore (CHL), a public health care facility in Pakistan with 1,000 new pediatric cancer admissions annually. The objective has been to reduce infections through collaboration between CHL and the St Jude Children's Hospital Global Infectious Disease program via a grant by the Sanofi Espoir foundation through the My Child Matters program. The aim of the current study was to describe the effect of the collaborative improvement strategy on existing infection prevention and control (IPC) standards at CHL. MATERIALS AND METHODS Our work was a prospective before-and-after study to improve IPC standards. We compared the WHO Hand Hygiene Self-Assessment Framework and four modules of the St Jude modified Infection Control Assessment Tool (ICAT) scores over a 3-year period. Our strategy included creating a multidisciplinary team of pediatric oncologists, infectious disease physicians, nurses, a microbiologist, and a data manager; engaging in monthly online IPC mentoring sessions with St Jude Children's Hospital Global Infectious Disease program and My Child Matters mentors; performing daily inpatient health care-associated infection surveillance rounds; and performing regular hand hygiene training and compliance audits. RESULTS Baseline needs assessment showed health care-associated infections identified by positive blood cultures as 8.7 infections per 1,000 patient-days. Deficient hand hygiene supplies, health education measures, and bed sharing of neutropenic patients were identified as major challenges. Our hand hygiene facility level, per WHO scores, increased from Inadequate to Intermediate/Consolidation by the end of the 3-year implementation (122 v 352 WHO Hand Hygiene Self-Assessment Framework scores). The sink:bed and hand sanitizer:bed ratios improved to 1:6 and 1:1, respectively. The ICAT general infection control module increased by 40% (45 v 78 ICAT scores) and hygiene compliance improved by 20%. CONCLUSION Implementing a collaborative improvement strategy improved IPC standards in our center, which can be easily replicated in other pediatric oncology centers in lower- and middle-income countries.
Collapse
Affiliation(s)
- Mahwish Faizan
- Department of Pediatric Hematology, Oncology and BMT, The Children's Hospital and Institute of Child Health, Lahore, Pakistan
| | - Miguela A Caniza
- Department of Microbiology, The Children's Hospital and Institute of Child Health, Lahore, Pakistan.,Department of Pediatric Cardiology, The Children's Hospital and Institute of Child Health, Lahore, Pakistan
| | - Saadia Anwar
- Department of Pediatric Hematology, Oncology and BMT, The Children's Hospital and Institute of Child Health, Lahore, Pakistan
| | - Rahat-Ul-Ain Kashif
- Department of Pediatric Hematology, Oncology and BMT, The Children's Hospital and Institute of Child Health, Lahore, Pakistan
| | - Rabia Saleem
- Department of Pediatric Hematology, Oncology and BMT, The Children's Hospital and Institute of Child Health, Lahore, Pakistan
| | - Humera Javed
- Department of Infectious Disease, St Jude Children's Research Hospital, Memphis, TN
| | - Aizza Zafar
- Department of Infectious Disease, St Jude Children's Research Hospital, Memphis, TN
| | - Mary Munaza Taj
- Departemnt of Global Pediatric Medicine, St Jude Children's Hospital, Memphis, TN
| | - Ambreen Hameed
- Department of Pediatric Hematology, Oncology and BMT, The Children's Hospital and Institute of Child Health, Lahore, Pakistan
| | - Maysam Homsi
- Department of Pediatric Cardiology, The Children's Hospital and Institute of Child Health, Lahore, Pakistan
| | - Ahsan Waheed Rathore
- Department of Pediatric Hematology, Oncology and BMT, The Children's Hospital and Institute of Child Health, Lahore, Pakistan
| | - Masood Sadiq
- Department of Pediatric Oncology, Royal Marsden Hospital, United Kingdom
| | - Miriam Gonzalez
- Department of Microbiology, The Children's Hospital and Institute of Child Health, Lahore, Pakistan.,Department of Pediatric Cardiology, The Children's Hospital and Institute of Child Health, Lahore, Pakistan
| | - Alia Zaidi
- Department of Pediatric Cardiology, The Children's Hospital and Institute of Child Health, Lahore, Pakistan
| |
Collapse
|
28
|
Seo SW, Ombengi D, Sultan DH, Kahaleh AA, Nonyel N, Karwa R, Abrons J, Lukas S, Singhal M, Miller M, Truong HA. An ethics-based approach to global health research part 1: Building partnerships in global health. Res Social Adm Pharm 2020; 16:1574-1579. [PMID: 32952088 DOI: 10.1016/j.sapharm.2020.08.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Revised: 08/28/2020] [Accepted: 08/30/2020] [Indexed: 01/23/2023]
Abstract
Global health partnerships (GHPs) can be the cornerstone for advancing research and public health. The steps to build a global research partnership focus on sharing a common research agenda, identifying key partners in the community, and establishing goals and expectations for partnerships. Moreover, upholding important values, such as communication, trust, and transparency is essential for building successful partnerships. Ethical dilemmas can propose challenges to researchers in global health. These challenges can be overcome by creating a shared vision for a research agenda, maintaining communication, and providing bidirectional training.
Collapse
Affiliation(s)
- See-Won Seo
- Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave, Albany, NY, 12208, USA.
| | - David Ombengi
- Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.
| | - Dawood H Sultan
- Mercer University College of Health Professions, 3001 Mercer University Drive, Atlanta, GA, 30341, USA.
| | - Abby A Kahaleh
- Roosevelt University College of Pharmacy, 1400 N Roosevelt Blvd, Schaumburg, IL, 13 60173, USA.
| | - Nkem Nonyel
- University of Maryland, Eastern Shore School of Pharmacy and Health Professions, Hazel Hall, Room 1041, Princess Anne, MD, 21853, USA.
| | - Rakhi Karwa
- Purdue University College of Pharmacy, 575 Stadium Mall Drive, West Lafayette, IN, 47907, USA.
| | - Jeanine Abrons
- University of Iowa College of Pharmacy, 180 S Grand Avenue, CP 354, Iowa City, IA, 52241, USA.
| | - Stephanie Lukas
- St. Louis College of Pharmacy, St. Louis, Missouri, 4588 Parkview Place, St. Louis, MO, 63110-1088, USA.
| | - Mudit Singhal
- D'Youville School of Pharmacy, 320 Porter Avenue, Buffalo, NY, 14201, USA.
| | - Monica Miller
- Purdue University College of Pharmacy, 575 Stadium Mall Drive, West Lafayette, IN, 47906, USA.
| | - Hoai-An Truong
- University of Maryland Eastern Shore, School of Pharmacy and Health Professions, 1 College Backbone Road, Princess Anne, MD, 21853, USA.
| |
Collapse
|
29
|
Communication about Traditional Complementary and Alternative Medicine (TCAM) in childhood cancer: A comparison between Dutch and Indonesian health-care providers at academic hospitals. ADVANCES IN INTEGRATIVE MEDICINE 2020. [DOI: 10.1016/j.aimed.2019.04.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
30
|
Challinor JM, Day SW, Afungchwi GM, Alqudimat MR. Pediatric Oncology Nursing Research in Low- and Middle-Income Countries. PEDIATRIC ONCOLOGY 2020. [DOI: 10.1007/978-3-030-25804-7_15] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
31
|
Psychological and spiritual wellbeing of family caregivers of children with cancer at a teaching hospital in Ghana. INTERNATIONAL JOURNAL OF AFRICA NURSING SCIENCES 2020. [DOI: 10.1016/j.ijans.2020.100231] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
32
|
Odiaka E, Lounsbury DW, Jalloh M, Adusei B, Diallo TA, Kane PMS, Rockson I, Okyne V, Irusen H, Pentz A, Makinde I, Ajibola OH, Petersen L, McBride J, Petersen DC, Mante S, Agalliu I, Adebiyi AO, Popoola O, Yeboah E, Mensah JE, Hsing A, Fernandez P, Aisuodionoe-Shadrach O, Joffe M, Singh E, Gueye SM, Quintana Y, Fortier B, Rebbeck TR, Andrews C. Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP). J Glob Oncol 2019; 4:1-12. [PMID: 30260756 PMCID: PMC6223501 DOI: 10.1200/jgo.18.00062] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose Health research in low- and middle-income countries can generate novel scientific knowledge and improve clinical care, fostering population health improvements to prevent premature death. Project management is a critical part of the success of this research, applying knowledge, skills, tools, and techniques to accomplish required goals. Here, we describe the development and implementation of tools to support a multifaceted study of prostate cancer in Africa, focusing on building strategic and operational capacity. Methods Applying a learning organizational framework, we developed and implemented a project management toolkit (PMT) that includes a management process flowchart, a cyclical center-specific schedule of activities, periodic reporting and communication, and center-specific monitoring and evaluation metrics. Results The PMT was successfully deployed during year one of the project with effective component implementation occurring through periodic cycles of dissemination and feedback to local center project managers. A specific evaluation was conducted 1 year after study initiation to obtain enrollment data, evaluate individual quality control management plans, and undertake risk log assessments and follow-up. Pilot data obtained identified areas in which centers required mentoring, strengthening, and capacity development. Strategies were implemented to improve project goals and operational capacity through local problem solving, conducting quality control checks and following compliancy with study aims. Moving forward, centers will perform quarterly evaluations and initiate strengthening measures as required. Conclusion The PMT has fostered the development of both strategic and operational capacity across project centers. Investment in project management resources is essential to ensuring high-quality, impactful health research in low- and middle-income countries.
Collapse
Affiliation(s)
- Emeka Odiaka
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - David W Lounsbury
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Mohamed Jalloh
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Ben Adusei
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Thierno Amadou Diallo
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Papa Moussa Sene Kane
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Isabella Rockson
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Vicky Okyne
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Hayley Irusen
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Audrey Pentz
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Ifeoluwa Makinde
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Olalekan Hafees Ajibola
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Lindsay Petersen
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Jo McBride
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Desiree C Petersen
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Sunny Mante
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Ilir Agalliu
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Akindele Olupelumi Adebiyi
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Olufemi Popoola
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Edward Yeboah
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - James E Mensah
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Ann Hsing
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Pedro Fernandez
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Oseremen Aisuodionoe-Shadrach
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Maureen Joffe
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Elvira Singh
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Serigne Magueye Gueye
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Yuri Quintana
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Brian Fortier
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Timothy R Rebbeck
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| | - Caroline Andrews
- Emeka Odiaka, Ifeoluwa Makinde, Akindele Olupelumi Adebiyi, and Olufemi Popoola, University College Hospital, Ibadan; Olalekan Hafees Ajibola and Oseremen Aisuodionoe-Shadrach, University of Abuja; Oseremen Aisuodionoe-Shadrach, University of Abuja Teaching Hospital, Abuja, Nigeria; David W. Lounsbury and Ilir Agalliu, Albert Einstein College of Medicine, Bronx, NY; Mohamed Jalloh, Thierno Amadou Diallo, Papa Moussa Sene Kane, and Serigne Magueye Gueye, Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal; Ben Adusei and Sunny Mante, 37 Military Hospital, Ghana; Isabella Rockson, Vicky Okyne, Edward Yeboah, and James E. Mensah, Korle-Bu Teaching Hospital, and University of Ghana, Accra, Ghana; Hayley Irusen and Pedro Fernandez, Stellenbosch University and Tygerberg Hospital; Lindsay Petersen, Jo McBride, and Desiree C. Petersen, Centre for Proteomic and Genomic Research, Cape Town; Audrey Pentz, Elvira Singh, and Maureen Joffe, University of the Witwatersrand, Johannesburg, South Africa; Ann Hsing, Stanford University, Stanford, CA; Yuri Quintana, Beth Israel Deaconess Medical Center; Brian Fortier, Timothy R. Rebbeck, and Caroline Andrews, Dana-Farber Cancer Institute; and Timothy R. Rebbeck, Harvard TH Chan School of Public Health, Boston, MA
| |
Collapse
|
33
|
Gupta T, Achari R, Chatterjee A, Chen ZP, Mehta M, Bouffet E, Jalali R. Comparison of Epidemiology and Outcomes in Neuro-Oncology Between the East and the West: Challenges and Opportunities. Clin Oncol (R Coll Radiol) 2019; 31:539-548. [PMID: 31182288 DOI: 10.1016/j.clon.2019.05.018] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Revised: 05/10/2019] [Accepted: 05/15/2019] [Indexed: 12/24/2022]
Abstract
Although neoplasms of the brain and central nervous system (CNS) are relatively uncommon, comprising only 1-2% of the overall cancer burden, they represent a substantial source of morbidity and mortality worldwide. The age-adjusted annual incidence of CNS tumours is reportedly low; however, there is substantial global variability in its incidence, with nearly a five-fold difference between regions with the highest rates in developed countries in the West and those with the lowest rates in developing countries in South-East Asia, including India, possibly attributable to key differences in environmental factors, genetic susceptibilities and cultural practices, as well as resource constraints in low-middle income countries precluding precise ascertainment and accurate diagnosis. The burden of CNS tumours is further compounded by the fact that they require highly specialised and skilled multidisciplinary care, including access to modern neuroimaging, neurosurgery, neuropathology and molecular biology, radiotherapy, chemotherapy and rehabilitation services, which may not be widely available in an integrated manner in large parts of the world with a large variation in clinical pathways, non-uniformity of care and resultant heterogeneity in clinical outcomes. CNS tumours encompass a heterogeneous spectrum of histopathological entities with differences in presentation, distinct molecular/genetic alterations, diverse biological behaviour and varying clinical outcomes. Survival is highly dependent on histology, grade and molecular biology, but varies widely across continents, even for the same tumour type and grade. In general, survival is higher in children with primary brain tumours than in adults, largely due to the differences in histological distribution across age groups. However, there is widespread variability, with 5-year survival for paediatric brain tumours being <40% in some low-middle income countries compared with 70-80% in the developed world. This review compares the descriptive epidemiology and clinical outcomes of primary brain tumours between the East and the West that pose unique challenges but also provide new opportunities in contemporary neuro-oncological practice.
Collapse
Affiliation(s)
- T Gupta
- Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India.
| | - R Achari
- Department of Radiation Oncology, Tata Medical Centre, Kolkata, India
| | - A Chatterjee
- Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India
| | - Z-P Chen
- Department of Neurosurgery, SunYat-sen University Cancer Centre, Guangzhou, China
| | - M Mehta
- Department of Radiation Oncology, Miami Cancer Institute, Miami, Florida, USA
| | - E Bouffet
- Neuro-Oncology Section, Division of Hematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada
| | - R Jalali
- Department of Radiation Oncology, Apollo Proton Cancer Centre, Chennai, India
| |
Collapse
|
34
|
Poon LHJ, Yu CP, Peng L, Ewig CLY, Zhang H, Li CK, Cheung YT. Clinical ascertainment of health outcomes in Asian survivors of childhood cancer: a systematic review. J Cancer Surviv 2019; 13:374-396. [PMID: 31055708 PMCID: PMC6548762 DOI: 10.1007/s11764-019-00759-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2018] [Accepted: 04/05/2019] [Indexed: 12/29/2022]
Abstract
PURPOSE Survivorship in children with cancer comes at a cost of developing chronic treatment-related complications. Yet, it is still an under-researched area in Asia, which shares the largest proportion of the global childhood cancer burden given its vast population. This systematic review summarizes existing literature on clinically ascertained health outcomes in Asian survivors of childhood cancer. METHODS A search was conducted on Ovid Medline and EMBASE for studies that focused on survivors of childhood cancer from countries in East and Southeast Asia; adopted post-treatment clinical ascertainment of organ-specific toxicities or/and secondary malignancy. Studies were excluded if health outcomes were assessed during the acute treatment. RESULTS Fifty-nine studies, enrolling a total of 13,442 subjects, were conducted on survivors of leukemia (34%), CNS tumor (14%), and cohorts of survivors with heterogeneous cancer diagnoses (52%). The studies used different medical evaluation methods to assess cardiovascular (15%), metabolic and infertility (32%), and neurological/neurocognitive (20%) outcomes in survivors. The collective findings suggest potential differences in the prevalence of certain late effects (e.g., secondary malignancy and obesity) among Asian and non-Asian populations, which may reflect differences in treatment regimens, practice, genetic variations, or/and socioeconomic disparity. CONCLUSIONS We recommend developing collaborative initiatives to build a regional repository of systematically assessed health outcomes and biospecimens to investigate treatment, social-environmental and genetic predictors, and interventions for late effects in this population. IMPLICATIONS FOR CANCER SURVIVORS The existing types of chronic health problems identified in this review suggest the need for active screening, better access to survivorship care, and promotion of protective health behavior in Asia.
Collapse
Affiliation(s)
- Long Hin Jonathan Poon
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, 8th Floor, Lo Kwee-Seong Integrated Biomedical Sciences Building, Shatin, N.T, Hong Kong
| | - Chun-Pong Yu
- Li Ping Medical Library, The Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Liwen Peng
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, 8th Floor, Lo Kwee-Seong Integrated Biomedical Sciences Building, Shatin, N.T, Hong Kong
| | - Celeste Lom-Ying Ewig
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, 8th Floor, Lo Kwee-Seong Integrated Biomedical Sciences Building, Shatin, N.T, Hong Kong
| | - Hui Zhang
- Department of Pediatric Hematology/Oncology, Guangzhou Women and Children's Medical Center, Guangzhou, China
| | - Chi-Kong Li
- Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong
- Paediatric Haematology & Oncology, Hong Kong Children's Hospital, Hong Kong, Hong Kong
| | - Yin Ting Cheung
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, 8th Floor, Lo Kwee-Seong Integrated Biomedical Sciences Building, Shatin, N.T, Hong Kong.
| |
Collapse
|
35
|
Eden T, Burns E, Freccero P, Renner L, Paintsil V, Dolendo M, Scanlan T, Khaing AA, Pina M, Islam A, Chunda-Liyoka C, Kouya F, Molyneux E. Are essential medicines available, reliable and affordable in low-middle income countries? J Cancer Policy 2019. [DOI: 10.1016/j.jcpo.2018.12.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
36
|
The Latin American Brain Tumor Board teleconference: results of a web-based survey to evaluate participant experience utilizing this resource. Childs Nerv Syst 2019; 35:257-265. [PMID: 30426208 DOI: 10.1007/s00381-018-4000-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2018] [Accepted: 11/01/2018] [Indexed: 01/12/2023]
Abstract
PURPOSE The Latin American Brain Tumor Board (LATB) is a weekly teleconference connecting pediatric neuro-oncologists from referral centers in high-income countries with pediatric subspecialists from 20 Latin American countries since 2013. This survey explored the participants' experience utilizing this resource. METHODS A cross-sectional electronic questionnaire was distributed to 159 participants through email and Cure4Kids. RESULTS Ninety-five respondents (60%) from all the participating countries completed the survey. Sixty-one reported frequent-attendance (≥ 1 per month), 23 reported infrequent-attendance (< 1 per month), and 11 never participated. The most frequently reported attendance-barriers were the subspecialist's workload (64%), the timing of the teleconference (38%), and Internet connectivity problems (29%). Subspecialist's workload was more frequently reported as a barrier compared with other barriers, in both the frequent- and infrequent-attendance groups (p < 0.05), with the exception of the timing of the meeting in the infrequent-attendance group. More than 80% of attendees found the frequency and duration of the teleconference were sufficient. Utilizing Spanish as the primary language was reported to enhance the recommendations by 93% of the attendees. Moreover, 84% reported that the recommendations (almost) always fit the local circumstances. Furthermore, 99% of attendees found the teleconference provided a continuing medical education opportunity. Finally, 96% of attendees (almost) always found that the provided recommendations helped to improve the outcomes/quality of life of the patients. CONCLUSIONS The LATB teleconference provided a valuable tool for the management of pediatric brain tumors in Latin America as it provided a feasible and easy to access continued medical education opportunity for the participants.
Collapse
|
37
|
Sirohi B, Chalkidou K, Pramesh CS, Anderson BO, Loeher P, El Dewachi O, Shamieh O, Shrikhande SV, Venkataramanan R, Parham G, Mwanahamuntu M, Eden T, Tsunoda A, Purushotham A, Stanway S, Rath GK, Sullivan R. Developing institutions for cancer care in low-income and middle-income countries: from cancer units to comprehensive cancer centres. Lancet Oncol 2018; 19:e395-e406. [PMID: 30102234 DOI: 10.1016/s1470-2045(18)30342-5] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2018] [Revised: 04/26/2018] [Accepted: 04/26/2018] [Indexed: 12/27/2022]
Abstract
Global cancer centres operate across different sizes, scales, and ecosystems. Understanding the essential aspects of the creation, organisation, accreditation, and activities within these settings is crucial for developing an affordable, equitable, and quality cancer care, research, and education system. Robust guidelines are scarce for cancer units, cancer centres, and comprehensive cancer centres in low-income and middle-income countries. However, some robust examples of the delivery of complex cancer care in centres in emerging economies are available. Although it is impossible to create an optimal system to fit the unique needs of all countries for the delivery of cancer care, we summarise what has been published about the development and management of cancer centres in low-income and middle-income countries so far and highlight the need for clinical and political leadership.
Collapse
Affiliation(s)
| | - Kalipso Chalkidou
- Imperial College London, London UK; Centre for Global Development, London, UK
| | | | | | - Patrick Loeher
- Indiana University Medical Center, Indianapolis, IN, USA
| | - Omar El Dewachi
- Global Health Institute, American University of Beirut, Beirut, Lebanon
| | | | | | | | | | | | - Tim Eden
- University of Manchester, Manchester, UK
| | - Audrey Tsunoda
- Hospital Erasto Gaertner, Instituto de Oncologia do Paraná and Universidade Positivo, Curitiba, Brazil
| | - Arnie Purushotham
- Tata Trusts, Mumbai, India; King's Health Partners Comprehensive Cancer Centre and Institute of Cancer Policy, School of Cancer Sciences, Kings College London, London, UK
| | | | - Goura K Rath
- All India Institute of Medical Sciences, New Delhi, India
| | - Richard Sullivan
- King's Health Partners Comprehensive Cancer Centre and Institute of Cancer Policy, School of Cancer Sciences, Kings College London, London, UK
| |
Collapse
|
38
|
|
39
|
Doherty M, Thabet C. Development and Implementation of a Pediatric Palliative Care Program in a Developing Country. Front Public Health 2018; 6:106. [PMID: 29713625 PMCID: PMC5911566 DOI: 10.3389/fpubh.2018.00106] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2018] [Accepted: 03/28/2018] [Indexed: 11/13/2022] Open
Abstract
Background Palliative care is recognized as an important component of care for children with cancer and other life-limiting conditions. In resource limited settings, palliative care is a key component of care for children with cancer and other life-limiting conditions. Globally, 98% of children who need palliative care live in low- or middle-income countries, where there are very few palliative care services available. There is limited evidence describing the practical considerations for the development and implementation of sustainable and cost-effective palliative care services in developing countries. Objectives Our aim is to describe the key considerations and initiatives that were successful in planning and implementing a hospital-based pediatric palliative care service specifically designed for a resource-limited setting. Setting Bangabandu Sheikh Mujib Medical University (BSMMU) is a tertiary referral hospital in Bangladesh. Local palliative care services are very limited and focused on adult patients. In partnership with World Child Cancer, a project establishing a pediatric palliative care service was developed for children with cancer at BSMMU. Results We describe four key elements which were crucial for the success of this program: (1) raising awareness and sensitizing hospital administrators and clinical staff about pediatric palliative care; (2) providing education and training on pediatric palliative care for clinical staff; (3) forming a pediatric palliative care team; and (4) collecting data to characterize the need for pediatric palliative care. Conclusion This model of a hospital-based pediatric palliative care service can be replicated in other resource-limited settings and can be expanded to include children with other life-limiting conditions. The development of pilot programs can generate interest among local physicians to become trained in pediatric palliative care and can be used to advocate for the palliative care needs of children.
Collapse
Affiliation(s)
- Megan Doherty
- Palliative Care Program, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.,University of Ottawa, Ottawa, ON, Canada.,Children's Palliative Care Initiative in Bangladesh, World Child Cancer, London, United Kingdom
| | | |
Collapse
|
40
|
Flanigan JS, Silkensen SL, Wolf NG. Global Health Pathology Research: Purpose and Funding. Clin Lab Med 2018; 38:21-35. [PMID: 29412883 PMCID: PMC5806131 DOI: 10.1016/j.cll.2017.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Like in all areas of science, it is important for funders and investigators of pathology to work together to develop a well-designed, well-executed clinical research agenda. In the first section of this article, the authors discuss how the National Institutes of Health (NIH) peer-review process applies to global health pathology research projects. Then, the authors present an illustrative sampling of NIH-funded projects with performance sites in low- and middle-income countries with 2 examples focused on cancer and anatomic pathology. Finally, the authors relate the research agenda to overarching strategic recommendations for enhancing global pathology.
Collapse
Affiliation(s)
- John S Flanigan
- Center for Global Health, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Rockville, MD 20850, USA.
| | - Shannon L Silkensen
- Center for Global Health, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Rockville, MD 20850, USA
| | - Nicholas G Wolf
- Center for Global Health, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Rockville, MD 20850, USA
| |
Collapse
|
41
|
Buswell L, Umuhizi D, Hategekimana V, Muhayimana C, Kennell-Heiling S. Voices of Hope From Rural Rwanda: Three Oncology Nurse Leaders Emerge. Oncol Nurs Forum 2017; 43:661-4. [PMID: 27541559 DOI: 10.1188/16.onf.661-664] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The cancer burden in low- and middle-income countries (LMICs) has been well described in the literature (International Agency for Research on Cancer, 2012; Ott, Ullrich, Mascarenhas, & Stevens, 2011; Thun, DeLancey, Center, Jemal, & Ward, 2010). According to the World Health Organization ([WHO], 2015), about 14 million new cancer cases occurred in 2012, and more than 60% of those cases were in Africa, Asia, and Central and South America; of the 8.2 million cancer-related deaths in 2012, more than 70% occurred in these regions (Bray & Møller, 2006).
.
Collapse
|
42
|
|
43
|
Challenges to Cancer Program Development in Low- and Middle-Income
Countries. Ann Glob Health 2016; 82:614-620. [DOI: 10.1016/j.aogh.2016.08.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
|
44
|
Rossell N, Challinor J, Gigengack R, Reis R. Choosing a miracle: Impoverishment, mistrust, and discordant views in abandonment of treatment of children with cancer in El Salvador. Psychooncology 2016; 26:1324-1329. [PMID: 27862585 DOI: 10.1002/pon.4302] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Revised: 09/16/2016] [Accepted: 10/31/2016] [Indexed: 12/15/2022]
Abstract
OBJECTIVE In El Salvador, at the only hospital offering pediatric oncology care, the number of children abandoning treatment for cancer has decreased in recent years (13%-3%). An investigation of caregivers' motives for abandonment was performed over 15 months from 2012 to 2014. Caregiver and health team perspectives on abandonment are reported using the explanatory model (EM) framework. METHOD Semistructured in-depth interviews and in hospital participant observations were conducted with caregivers of children diagnosed with cancer, who abandoned their child's treatment or were considering abandoning, and with members of the medical team. RESULTS Of the 41 caregivers interviewed, 26 caregivers (of 19 children) abandoned their child's treatment, returned from a series of missed appointments, or showed a risk of abandoning. Caregivers of 8 children stated that a miraculous cure was the main reason for abandoning; increasing impoverishment and misgivings toward treatment and outcomes were also mentioned. The responses of the medical team demonstrated a discordant EM for the child's cancer and treatment effects and that only biomedical treatment was effective for cure. CONCLUSIONS The caregivers' increasing impoverishment (not only financial) and misgivings about the child's treatment caused them to reconsider their therapeutic choices and rely on their belief in a miraculous cure, thus abandoning. The caregivers and medical team's discordant EM about the child's cancer and treatment must be acknowledged and shared decision making considered, together with consistency in the strategies that currently demonstrate to be effective decreasing abandonment.
Collapse
Affiliation(s)
- Nuria Rossell
- Amsterdam Institute for Social Sciences Research (AISSR), University of Amsterdam, Amsterdam, The Netherlands
| | - Julia Challinor
- Department of Physiological Nursing, School of Nursing, University of California San Francisco, California, USA
| | - Roy Gigengack
- Department of Social and Cultural Anthropology, Vrije Universiteit, Amsterdam, The Netherlands
| | - Ria Reis
- Amsterdam Institute for Social Sciences Research (AISSR), University of Amsterdam, Amsterdam, The Netherlands.,Leiden University Medical Center, Leiden, The Netherlands.,School of Child and Adolescent Health, The Children's Institute, University of Cape Town, South Africa
| |
Collapse
|
45
|
Cadée F, Nieuwenhuijze MJ, Lagro-Janssen ALM, De Vries R. The state of the art of twinning, a concept analysis of twinning in healthcare. Global Health 2016; 12:66. [PMID: 27784312 PMCID: PMC5080707 DOI: 10.1186/s12992-016-0205-5] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2016] [Accepted: 10/11/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Inequities in health have garnered international attention and are now addressed in Sustainable Development Goal 3 (SDG3), which seeks to 'promote well-being for all'. To attain this goal globally requires innovative approaches, one of which is twinning. According to the International Confederation of Midwives, twinning focusses on empowering professionals, who can subsequently be change-agents for their communities. However, twinning in healthcare is relatively new and because the definition and understanding of twinning lacks clarity, rigorous monitoring and evaluation are rare. A clear definition of twinning is essential for the development of a scientific base for this promising form of collaboration. METHOD We conducted a Concept Analysis (CA) of twinning in healthcare using Morse's method. A qualitative study of the broad literature was performed, including scientific papers, manuals, project reports, and websites. We identified relevant papers through a systematic search using scientific databases, backtracking of references, and experts in the field. RESULTS We found nineteen papers on twinning in healthcare. This included twelve peer reviewed research papers, four manuals on twinning, two project reports, and one website. Seven of these papers offered no definition of twinning. In the other twelve papers definitions varied. Our CA of the literature resulted in four main attributes of twinning in healthcare. First, and most frequently mentioned, was reciprocity. The other three attributes were that twinning: 2) entails the building of personal relationships, 3) is dynamic process, 4) is between two named organisations across different cultures. The literature also indicated that these four attributes, and especially reciprocity, can have an empowering effect on healthcare professionals. CONCLUSIONS Based on these four attributes we developed the following operational definition: Twinning is a cross-cultural, reciprocal process where two groups of people work together to achieve joint goals. A greater understanding and a mature definition of twinning results in clear expectations for participants and thus more effective twinning. This can be the starting point for new collaborations and for further international studies on the effect of twinning in healthcare.
Collapse
Affiliation(s)
- Franka Cadée
- CAPHRI School for Public Health and Primary Care, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands. .,Research Centre for Midwifery Science, Zuyd University, Universiteitssingel 60, 6229 ER, Maastricht, The Netherlands.
| | - Marianne J Nieuwenhuijze
- Research Centre for Midwifery Science Maastricht, Zuyd University, Universiteitssingel 60, 6229 ER, Maastricht, The Netherlands
| | - A L M Lagro-Janssen
- Department of Primary and Community Care, Gender and Women's Health, Radboud University Medical Center, P.O.Box 9101, 6500 HB, Nijmegen, The Netherlands
| | - Raymond De Vries
- Center for Bioethics and Social Sciences in Medicine University of Michigan Medical School, North Campus Research Complex, 2800 Plymouth Road, Building 16, 419W, Ann Arbor, MI, 48109-2800, USA.,CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands
| |
Collapse
|
46
|
Enhancement of oncology nursing education in low- and middle-income countries: Challenges and strategies. J Cancer Policy 2016. [DOI: 10.1016/j.jcpo.2016.03.002] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
47
|
Abstract
Cancer is now recognized as one of the four leading causes of morbidity and mortality worldwide, and incidence is expected to rise significantly in the next two decades. Unfortunately, low- and middle-income countries (LMIC) suffer disproportionately from the world's cancer cases. The growing burden of cancer and maldistribution of cancer care resources in LMIC warrant a massive re-evaluation of the structural inequalities that produce global oncological disparities and a worldwide commitment to improve both prevention and treatment strategies. Efforts to improve cancer care capacity should focus on horizontal strengthening of healthcare systems that provide safe, affordable, effective and sustainable care. In response to current deficiencies, many international organizations have started to partner with LMIC to create solutions. Telemedicine and international collaboration are also promising ways to effect change and improve global oncological care.
Collapse
Affiliation(s)
- Madeline Pesec
- Brown University 6683, 69 Brown Street, Providence, RI 02912, USA
| | - Tracy Sherertz
- Department of Radiation Oncology, University of California, San Francisco, 1600 Divisadero St, Suite H-1031, San Francisco, CA 94115, USA
| |
Collapse
|
48
|
|
49
|
Ribeiro RC, Antillon F, Pedrosa F, Pui CH. Global Pediatric Oncology: Lessons From Partnerships Between High-Income Countries and Low- to Mid-Income Countries. J Clin Oncol 2015; 34:53-61. [PMID: 26578620 DOI: 10.1200/jco.2015.61.9148] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Partnerships between medical institutions in high-income countries (HICs) and low- to mid-income countries (LMICs) have succeeded in initiating and expanding pediatric cancer control efforts. The long-term goal is consistently a sustainable national pediatric cancer program. Here, we review the elements required for successful implementation, development, and long-term sustainability of pediatric cancer programs in LMICs that first arise as partnerships with institutions in HICs. Although plans must be adapted to each country's resources, certain components are unfailingly necessary. First, an essential step is provision of treatment regardless of ability to pay. Second, financial support for program development and long-term sustainability must be sought from sources both international and local, public and private. A local leader, typically a well-trained pediatric oncologist who devotes full-time effort to the project, should direct medical care and collaborate with hospital, governmental, and community leadership and international agencies. Third, nurses must be trained in pediatric cancer care and allowed to practice this specialty full-time. It is also essential to develop a grassroots organization, such as a foundation, dedicated solely to pediatric oncology. Its members must be trained and educated to provide pediatric cancer advocacy, fundraising, and (in concert with government) program sustainability. Finally, a project mentor in the HIC is crucial and should explore the possibility of collaborative research in the LMIC, which may offer significant opportunities. Relationships between the partnership's leaders and influential individuals in the community, hospital, grassroots foundation, and government will lay the foundation for productive collaboration and a sustainable pediatric oncology program.
Collapse
Affiliation(s)
- Raul C Ribeiro
- Raul C. Ribeiro and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Federico Antillon, Unidad Nacional de Oncologia Pediatrica and Universidad Francisco Marroquin, Guatemala City, Guatemala; and Francisco Pedrosa, Instituto de Medicina Integral Fernando Figueira, Recife, Brazil.
| | - Federico Antillon
- Raul C. Ribeiro and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Federico Antillon, Unidad Nacional de Oncologia Pediatrica and Universidad Francisco Marroquin, Guatemala City, Guatemala; and Francisco Pedrosa, Instituto de Medicina Integral Fernando Figueira, Recife, Brazil
| | - Francisco Pedrosa
- Raul C. Ribeiro and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Federico Antillon, Unidad Nacional de Oncologia Pediatrica and Universidad Francisco Marroquin, Guatemala City, Guatemala; and Francisco Pedrosa, Instituto de Medicina Integral Fernando Figueira, Recife, Brazil
| | - Ching-Hon Pui
- Raul C. Ribeiro and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Federico Antillon, Unidad Nacional de Oncologia Pediatrica and Universidad Francisco Marroquin, Guatemala City, Guatemala; and Francisco Pedrosa, Instituto de Medicina Integral Fernando Figueira, Recife, Brazil
| |
Collapse
|
50
|
The surgeon's role in childhood cancer worldwide. Lancet Oncol 2015; 16:1191-2. [PMID: 26427362 DOI: 10.1016/s1470-2045(15)00293-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2015] [Accepted: 08/28/2015] [Indexed: 11/23/2022]
|